Insights into the molecular mechanisms of diabetes-induced endothelial dysfunction: focus on oxidative stress and endothelial progenitor cells

Endocrine

Volumn 50, Issue 3, 2015, Pages 537-567

  Saad, Mohamed I ^a,b   Abdelkhalek, Taha M ^a   Saleh, Moustafa M ^a   Kamel, Maher A ^a   Youssef, Mina ^c   Tawfik, Shady H ^d   Dominguez, Helena ^e  

^a ALEXANDRIA UNIVERSITY   (Egypt)

^b MONASH UNIVERSITY   (Australia)

^c MCGILL UNIVERSITY   (Canada)

^d UNIVERSITY OF PADOVA   (Italy)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Diabetes; Endothelial dysfunction; Endothelial progenitor cells; Oxidative stress

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; ALDOSE REDUCTASE INHIBITOR; APELIN; C REACTIVE PROTEIN; CERAMIDE; CHEMERIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; EXENDIN 4; GHRELIN; GLUCAGON LIKE PEPTIDE 1; HEXOSAMINE; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 6; LEPTIN; LIRAGLUTIDE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; OBESTATIN; OMENTIN; RESISTIN; SITAGLIPTIN; STEARIC ACID; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASPIN; VILDAGLIPTIN; INCRETIN;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; ATHEROSCLEROSIS; BIOACCUMULATION; BIOAVAILABILITY; CARDIOVASCULAR DISEASE; CELL HOMING; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; CLINICAL TRIAL (TOPIC); DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DISEASE ASSOCIATION; DYSLIPIDEMIA; ENDOPLASMIC RETICULUM STRESS; ENDOTHELIAL DYSFUNCTION; ENDOTHELIAL PROGENITOR CELL; ENZYME ACTIVATION; ENZYME INHIBITION; GLYCATION; HEMATOPOIETIC STEM CELL; HUMAN; HYPERGLYCEMIA; IN VITRO STUDY; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; LIPID DIET; META ANALYSIS (TOPIC); MOLECULAR PATHOLOGY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; UPREGULATION; VASCULAR SMOOTH MUSCLE CELL; ANIMAL; DIABETES MELLITUS; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; VASCULAR ENDOTHELIUM;

ADIPOKINES; ANIMALS; DIABETES MELLITUS; DYSLIPIDEMIAS; ENDOTHELIAL PROGENITOR CELLS; ENDOTHELIUM, VASCULAR; GHRELIN; HUMANS; HYPERGLYCEMIA; INCRETINS; INFLAMMATION; INSULIN RESISTANCE; OXIDATIVE STRESS;

EID: 84949090591     PISSN: 1355008X     EISSN: 15590100     Source Type: Journal    
DOI: 10.1007/s12020-015-0709-4     Document Type: Review

References (389)

1. Association AD, Diagnosis and classification of diabetes mellitus. Diabetes care 36(Supplement 1), S67–S74 (2013)
2. P.Z. Zimmet, D.J. Magliano, W.H. Herman, J.E. Shaw, Diabetes: a 21st century challenge. Lancet Diabetes Endocrinol 2(1), 56–64 (2014)
3. R.A. Defronzo, Banting lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 58(4), 773–795 (2009)
4. Y. Lin, Z. Sun, Current views on type 2 diabetes. J. Endocrinol. 204(1), 1–11 (2010)
5. E. Hopps, D. Noto, G. Caimi, M. Averna, A novel component of the metabolic syndrome: the oxidative stress. Nutr Metab Cardiovasc Dis 20(1), 72–77 (2010)
6. J.S. Johansen, A.K. Harris, D.J. Rychly, A. Ergul, Oxidative stress and the use of antioxidants in diabetes: linking basic science to clinical practice. Cardiovasc Diabetol 4(1), 5 (2005)
7. G. Cohen, Y. Riahi, E. Alpert, A. Gruzman, S. Sasson, The roles of hyperglycaemia and oxidative stress in the rise and collapse of the natural protective mechanism against vascular endothelial cell dysfunction in diabetes. Arch. Physiol. Biochem. 113(4–5), 259–267 (2007)
8. S. Ansar, J. Koska, P.D. Reaven et al., Postprandial hyperlipidemia, endothelial dysfunction and cardiovascular risk: focus on incretins. Cardiovasc. Diabetol. 10(1), 61 (2011)
9. D. Versari, E. Daghini, A. Virdis, L. Ghiadoni, S. Taddei, Endothelial dysfunction as a target for prevention of cardiovascular disease. Diabetes care 32(Suppl 2), S314–S321 (2009)
10. R.J. Esper, R.A. Nordaby, J.O. Vilariño, A. Paragano, J.L. Cacharrón, R.A. Machado et al., Endothelial dysfunction: a comprehensive appraisal. Cardiovasc Diabetol. 5(4), 4–22 (2006)
11. C.N. Marti, M. Gheorghiade, A.P. Kalogeropoulos, V.V. Georgiopoulou, A.A. Quyyumi, J. Butler, Endothelial dysfunction, arterial stiffness, and heart failure. J. Am. Coll. Cardiol. 60(16), 1455–1469 (2012)
12. S. Hamed, B. Brenner, A. Aharon, D. Daoud, A. Roguin, Nitric oxide and superoxide dismutase modulate endothelial progenitor cell function in type 2 diabetes mellitus. Cardiovasc Diabetol. 8(56), 666–674 (2009)
13. F. Timmermans, J. Plum, M.C. Yöder, D.A. Ingram, B. Vandekerckhove, J. Case, Endothelial progenitor cells: identity defined? J. Cell Mol. Med. 13(1), 87–102 (2009)
14. D.P. Basile, M.C. Yoder, Circulating and tissue resident endothelial progenitor cells. J. Cell. Physiol. 229(1), 10–16 (2014)
15. R.M. Cubbon, A. Rajwani, S.B. Wheatcroft, The impact of insulin resistance on endothelial function, progenitor cells and repair. Diabetes Vasc. Dis. Res. 4(2), 103–111 (2007)
16. M.C. Yoder, Human endothelial progenitor cells. Cold Spring Harbor perspectives in medicine. Cold Spring: Harbor Laboratory Press; 2012;2(7):a006692 (2012). doi:10.1101/cshperspect.a006692
17. M. Zhang, A.B. Malik, J. Rehman, Endothelial progenitor cells and vascular repair. Curr. Opin. Hematol. 21(3), 224–228 (2014)
18. P. Staller, J. Sulitkova, J. Lisztwan, H. Moch, E.J. Oakeley, W. Krek, Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL. Nature 425(6955), 307–311 (2003)
19. D.J. Ceradini, A.R. Kulkarni, M.J. Callaghan, O.M. Tepper, N. Bastidas, M.E. Kleinman et al., Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat. Med. 10(8), 858–864 (2004)
20. A. Avogaro, G.P. Fadini, A. Gallo, E. Pagnin, S. de Kreutzenberg, Endothelial dysfunction in type 2 diabetes mellitus. Nutr. Metab. Cardiovasc. Dis. 16, S39–S45 (2006)
21. M. Gili, A. Orsello, S. Gallo, M.F. Brizzi, Diabetes-associated macrovascular complications: cell-based therapy a new tool? Endocrine 44(3), 557–575 (2013)
22. T. Thum, D. Fraccarollo, M. Schultheiss, S. Froese, P. Galuppo, J.D. Widder et al., Endothelial nitric oxide synthase uncoupling impairs endothelial progenitor cell mobilization and function in diabetes. Diabetes 56(3), 666–674 (2007)
23. L. Bruyndonckx, V.Y. Hoymans, G. Frederix, A. Guchtenaere, H. Franckx, D.K. Vissers et al., Endothelial progenitor cells and endothelial microparticles are independent predictors of endothelial function. J. Pediatr. 165(2), 300–305 (2014)
24. M.F. Lombardo, P. Iacopino, M. Cuzzola, E. Spiniello, C. Garreffa, F. Ferrelli et al., Type 2 diabetes mellitus impairs the maturation of endothelial progenitor cells and increases the number of circulating endothelial cells in peripheral blood. Cytom. Part A 81(10), 856–864 (2012)
25. M. Frisard, E. Ravussin, Energy metabolism and oxidative stress. Endocrine 29(1), 27–32 (2006)
26. J. Tanaka, L. Qiang, A.S. Banks, C.L. Welch, M. Matsumoto, T. Kitamura et al., Foxo 1 links hyperglycemia to LDL oxidation and endothelial nitric oxide synthase dysfunction in vascular endothelial cells. Diabetes 58(10), 2344–2354 (2009)
27. K. Tsuchiya, J. Tanaka, Y. Shuiqing, C.L. Welch, R.A. DePinho, I. Tabas et al., FoxOs integrate pleiotropic actions of insulin in vascular endothelium to protect mice from atherosclerosis. Cell Metab. 15(3), 372–381 (2012)
28. F. Yan, Y. Wang, X. Wu, H.M. Peshavariya, G.J. Dusting, M. Zhang et al., Nox4 and redox signaling mediate TGF-β-induced endothelial cell apoptosis and phenotypic switch. Cell Death Dis. 5, e1010 (2014). doi:10.1038/cddis.2013.551
29. V. Romaschenko, R. Zinovkin, I. Galkin, V. Zakharova, A. Panteleeva, A. Tokarchuk et al., Low concentrations of uncouplers of oxidative phosphorylation prevent inflammatory activation of endothelial cells by tumor necrosis factor. Biochemistry (Moscow) 80(5), 610–619 (2015)
30. M.T. Mathews, B.C. Berk, PARP-1 inhibition prevents oxidative and nitrosative stress-induced endothelial cell death via transactivation of the VEGF receptor 2. Arterioscler. Thromb. Vasc. Biol. 28(4), 711–717 (2008)
31. L. Gong, F. Liu, J. Wang, X. Wang, X. Hou, Y. Sun et al., yperglycemia induces apoptosis of pancreatic islet endothelial cells via reactive nitrogen species-mediated Jun N-terminal kinase activation. Mol. Cell Res. 1813(6), 1211–1219 (2011)
32. A. Vikram, Y.-R. Kim, S. Kumar, A. Naqvi, T.A. Hoffman, A. Kumar et al., Canonical Wnt signaling induces vascular endothelial dysfunction via p66Shc-regulated reactive oxygen species. Arterioscler. Thrombos. Vasc. Biol. 34(10), 2301–2309 (2014)
33. J. Case, D.A. Ingram, L.S. Haneline, Oxidative stress impairs endothelial progenitor cell function. Antioxid. Redox Signal. 10(11), 1895–1907 (2008)
34. D. Sukmawati, S. Fujimura, S. Jitsukawa, R. Ito-Hirano, T. Ishii, T. Sato et al., Oxidative stress tolerance of early stage diabetic endothelial progenitor cell. Regener. Therapy 1, 38–44 (2015)
35. F. Wang, Y.-Q. Wang, Q. Cao, J.-J. Zhang, L.-Y. Huang, T.-T. Sang et al., Hydrogen peroxide induced impairment of endothelial progenitor cell viability is mediated through a FoxO3a dependant mechanism. Microvasc. Res. 90, 48–54 (2013)
36. A. Rosso, A. Balsamo, R. Gambino, P. Dentelli, R. Falcioni, M. Cassader et al., p53 Mediates the accelerated onset of senescence of endothelial progenitor cells in diabetes. J. Biol. Chem. 281(7), 4339–4347 (2006)
37. J. Song, Y. Lee, Differential role of glutaredoxin and thioredoxin in metabolic oxidative stress-induced activation of apoptosis signal-regulating kinase 1. Biochem. J. 373, 845–853 (2003)
38. D.A. Ingram, T.R. Krier, L.E. Mead, C. McGuire, D.N. Prater, J. Bhavsar et al., Clonogenic endothelial progenitor cells are sensitive to oxidative stress. Stem Cells 25(2), 297–304 (2007)
39. J. Wei, Y. Liu, M. Chang, C.-L. Sun, D.-W. Li, Z.-Q. Liu et al., Proteomic analysis of oxidative modification in endothelial colony-forming cells treated by hydrogen peroxide. Int. J. Mol. Med. 29(6), 1099–1105 (2012)
40. N. Musi, L.J. Goodyear, Insulin resistance and improvements in signal transduction. Endocrine 29(1), 73–80 (2006)
41. H.C. Lam, Role of endothelin in diabetic vascular complications. Endocrine 14(3), 277–284 (2001)
42. K. Cusi, K. Maezono, A. Osman, M. Pendergrass, M.E. Patti, T. Pratipanawatr et al., Insulin resistance differentially affects the PI 3-kinase-and MAP kinase-mediated signaling in human muscle. J. Clin. Investig. 105(3), 311 (2000)
43. E.C. Eringa, C.D.A. Stehouwer, G.P. van Nieuw Amerongen, L. Ouwehand, N. Westerhof, P. Sipkema, Vasoconstrictor effects of insulin in skeletal muscle arterioles are mediated by ERK1/2 activation in endothelium. Am. J. Physiol. Heart Circ. Physiol. 287(5), H2043–H2048 (2004)
44. W.A. Hsueh, R.E. Law, Insulin signaling in the arterial wall. Am. J. Cardiol. 84(1A), 21J–24J (1999)
45. P.V. Katakam, J.A. Snipes, M.M. Steed, D.W. Busija, Insulin-induced generation of reactive oxygen species and uncoupling of nitric oxide synthase underlie the cerebrovascular insulin resistance in obese rats. J. Cereb. Blood Flow Metab. 32(5), 792–804 (2012)
46. U. Förstermann, T. Münzel, Endothelial nitric oxide synthase in vascular disease from marvel to menace. Circulation 113(13), 1708–1714 (2006)
47. M. Yokoyama, K. Hirata, Endothelial nitric oxide synthase uncoupling: is it a physiological mechanism of endothelium-dependent relaxation in cerebral artery? Cardiovasc. Res. 73(1), 8–9 (2007)
48. J. Vásquez-Vivar, B. Kalyanaraman, P. Martásek, N. Hogg, B.S. Masters, H. Karoui et al., Superoxide generation by endothelial nitric oxide synthase: the influence of cofactors. Proc. Natl. Acad. Sci. U.S.A. 95(16), 9220–9225 (1998)
49. T. Sugiyama, B.D. Levy, T. Michel, Tetrahydrobiopterin recycling, a key determinant of endothelial nitric-oxide synthase-dependent signaling pathways in cultured vascular endothelial cells. J. Biol. Chem. 284(19), 12691–12700 (2009)
50. J.G. San, J. Bidegain, P.A. Robador, J. Díez, A. Fortuño, G. Zalba, Insulin-induced NADPH oxidase activation promotes proliferation and matrix metalloproteinase activation in monocytes/macrophages. Free Radic. Biol. Med. 46(8), 1058–1067 (2009)
51. A. Görlach, R. Brandes, K. Nguyen, M. Amidi, F. Dehghani, R. Busse, A gp91phox containing NADPH oxidase selectively expressed in endothelial cells is a major source of oxygen radical generation in the arterial wall. Circ. Res. 87(1), 26–32 (2000)
52. G. Douglas, J.K. Bendall, M.J. Crabtree, A.L. Tatham, E.E. Carter, A.B. Hale et al., Endothelial-specific Nox2 overexpression increases vascular superoxide and macrophage recruitment in ApoE-/- mice. Cardiovasc. Res. 94(1), 20–29 (2012)
53. T. Ago, T. Kitazono, H. Ooboshi, T. Iyama, Y.H. Han, J. Takada et al., Nox4 as the major catalytic component of an endothelial NAD(P)H oxidase. Circulation 109(2), 227–233 (2004)
54. S. Furukawa, T. Fujita, M. Shimabukuro, M. Iwaki, Y. Yamada, Y. Nakajima et al., Increased oxidative stress in obesity and its impact on metabolic syndrome. J. Clin. Investig. 114(12), 1752 (2004)
55. G. Ceolotto, M. Bevilacqua, I. Papparella, E. Baritono, L. Franco, C. Corvaja et al., Insulin generates free radicals by an NAD (P) H, phosphatidylinositol 3′-kinase-dependent mechanism in human skin fibroblasts ex vivo. Diabetes 53(5), 1344–1351 (2004)
56. D. Zhuang, A.-C. Ceacareanu, Y. Lin, B. Ceacareanu, M. Dixit, K.E. Chapman et al., Nitric oxide attenuates insulin-or IGF-I-stimulated aortic smooth muscle cell motility by decreasing H2O2 levels: essential role of cGMP. Am. J. Physiol.-Heart Circ. Physiol. 286(6), H2103–H2112 (2004)
57. K. Shinozaki, T. Okamura, Y. Nishio, A. Kashiwagi, R. Kikkawa, N. Toda, Evaluation of endothelial free radical release by vascular tension responses in insulin-resistant rat aorta. Eur. J. Pharmacol. 394(2–3), 295–299 (2000)
58. C. Murphy, G.S. Kanaganayagam, B. Jiang, P.J. Chowienczyk, R. Zbinden, M. Saha et al., Vascular dysfunction and reduced circulating endothelial progenitor cells in young healthy UK South Asian men. Arterioscler. Thromb. Vasc. Biol. 27(4), 936–942 (2007)
59. P.M. Humpert, Z. Djuric, U. Zeuge, D. Oikonomou, Y. Seregin, K. Laine et al., Insulin stimulates the clonogenic potential of angiogenic endothelial progenitor cells by IGF-1 receptor-dependent signaling. Mol. Med. 14(5–6), 301 (2008)
60. N.Y. Yuldasheva, S.T. Rashid, N.J. Haywood, P. Cordell, R. Mughal, H. Viswambharan et al., Haploinsufficiency of the insulin-like growth factor-1 receptor enhances endothelial repair and favorably modifies angiogenic progenitor cell phenotype. Arterioscler. Thrombos. Vasc. Biol. 34(9), 2051–2058 (2014)
61. L. Benboubker, H. Watier, A. Carion, M.-T. Georget, I. Desbois, P. Colombat et al., Association between the SDF1-3′ A allele and high levels of CD34+ progenitor cells mobilized into peripheral blood in humans. Br. J. Haematol. 113(1), 247–250 (2001)
62. A. Sengupta, H. Viswambharan, N. Yuldasheva, B. Mercer, S. Galloway, N. Ali et al., Endothelial insulin sensitisation enhances vascular repair in systemic insulin resistance and improves endothelial function by restoring nitric oxide bioavailability. Circulation 130(2), A13829 (2014)
63. M.B. Kahn, N.Y. Yuldasheva, R.M. Cubbon, J. Smith, S.T. Rashid, H. Viswambharan et al., Insulin resistance impairs circulating angiogenic progenitor cell function and delays endothelial regeneration. Diabetes 60(4), 1295–1303 (2011)
64. M.M. Hartge, T. Unger, U. Kintscher, The endothelium and vascular inflammation in diabetes. Diabetes Vasc. Dis. Res. 4(2), 84–88 (2007)
65. R.B. Goldberg, Cytokine and cytokine-like inflammation markers, endothelial dysfunction, and imbalanced coagulation in development of diabetes and its complications. J. Clin. Endocrinol. Metab. 94(9), 3171–3182 (2009)
66. T. Yang, C.-H. Chu, P.-C. Hsieh, C.-H. Hsu, Y.-C. Chou, S.-H. Yang et al., C-reactive protein concentration as a significant correlate for metabolic syndrome: a Chinese population-based study. Endocrine 43(2), 351–359 (2013)
67. S. Ma, Y. Jin, W. Xu, W. Hu, F. Bai, X. Wu, Increased serum levels of ischemia-modified albumin and C-reactive protein in type 1 diabetes patients with ketoacidosis. Endocrine 42(3), 570–576 (2012)
68. A.D. Pradhan, J.E. Manson, N. Rifai, J.E. Buring, P.M. Ridker, C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 286(3), 327–334 (2001)
69. D.J. Freeman, J. Norrie, M.J. Caslake, A. Gaw, I. Ford, G.D. Lowe et al., C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes 51(5), 1596–1600 (2002)
70. S. Devaraj, P.R. Kumaresan, I. Jialal, C-reactive protein induces release of both endothelial microparticles and circulating endothelial cells in vitro and in vivo: further evidence of endothelial dysfunction. Clin. Chem. 57(12), 1757–1761 (2011)
71. Y. Fujita, S. Yamaguchi, A. Kakino, S. Iwamoto, R. Yoshimoto, T. Sawamura, Lectin-like oxidized LDL receptor 1 is involved in CRP-mediated complement activation. Clin. Chem. 57(10), 1398–1405 (2011)
72. K. Tanigaki, C. Mineo, I.S. Yuhanna, K.L. Chambliss, M.J. Quon, E. Bonvini et al., C-reactive protein inhibits insulin activation of endothelial nitric oxide synthase via the immunoreceptor tyrosine-based inhibition motif of Fc RIIB and SHIP-1. Circ. Res. 104(11), 1275–1282 (2009)
73. X. Wang, W. Liu, Y. Wu, X. Liu, X. Liang, Z. Wan et al., C-reactive protein reduces protein S-nitrosylation in endothelial cells. Mol. Cell. Biochem. 375(1–2), 131–138 (2013)
74. Y. Zhong, C. Cheng, Y. Luo, C. Tian, H. Yang, B. Liu et al., C-reactive protein stimulates RAGE expression in human coronary artery endothelial cells in vitro via ROS generation and ERK/NF κB activation. Acta Pharmacol. Sinica 36, 440–447 (2015)
75. J. Chen, J. Jin, M. Song, H. Dong, G. Zhao, L. Huang, C-reactive protein down-regulates endothelial nitric oxide synthase expression and promotes apoptosis in endothelial progenitor cells through receptor for advanced glycation end-products. Gene 496(2), 128–135 (2012)
76. H. Fujii, S.-H. Li, P.E. Szmitko, P.W. Fedak, S. Verma, C-reactive protein alters antioxidant defenses and promotes apoptosis in endothelial progenitor cells. Arterioscler. Thrombos. Vasc. Biol. 26(11), 2476–2482 (2006)
77. K.A. Fasing, B.J. Nissan, J.J. Greiner, B.L. Stauffer, C.A. DeSouza, Influence of elevated levels of C-reactive protein on circulating endothelial progenitor cell function. Clin. Transl. Sci. 7(2), 137–140 (2014)
78. K. Yamagata, N. Tanaka, H. Matsufuji, M. Chino, β-Carotene reverses the IL-1βmediated reduction in paraoxonase-1 expression via induction of the CaMKKII pathway in human endothelial cells. Microvasc. Res. 84(3), 297–305 (2012)
79. S. Vallejo, E. Palacios, T. Romacho, L. Villalobos, C. Peiró, C.F. Sánchez-Ferrer, The interleukin-1 receptor antagonist anakinra improves endothelial dysfunction in streptozotocin-induced diabetic rats. Cardiovasc. Diabetol. 13(1), 158 (2014)
80. A. Rosell, K. Arai, J. Lok, T. He, S. Guo, M. Navarro et al., Interleukin-1β augments angiogenic responses of murine endothelial progenitor cells in vitro. J. Cereb. Blood Flow Metab. 29(5), 933–943 (2009)
81. L. Yang, X.-G. Guo, C.-Q. Du, J.-X. Yang, D.-M. Jiang, B. Li et al., Interleukin-1 beta increases activity of human endothelial progenitor cells: involvement of PI3K-Akt signaling pathway. Inflammation 35(4), 1242–1250 (2012)
82. A. Mao, C. Liu, Y. Guo, D. Su, T. Luo, W. Fu et al., Modulation of the number and functions of endothelial progenitor cells by interleukin 1 in the peripheral blood of pigs: involvement of p38 mitogen-activated protein kinase signaling in vitro. J. Trauma Acute Care Surg. 73(5), 1145–1151 (2012)
83. M. Lagman, J. Ly, T. Saing, S.M. Kaur, T.E. Vera, D. Morris et al., Investigating the causes for decreased levels of glutathione in individuals with type II diabetes. PLoS ONE 10(3), e0118436 (2015). doi:10.1371/journal.pone.0118436
84. B. Thorand, H. Kolb, J. Baumert, W. Koenig, L. Chambless, C. Meisinger et al., Elevated levels of interleukin-18 predict the development of type 2 diabetes results from the MONICA/KORA Augsburg study, 1984-2002. Diabetes 54(10), 2932–2938 (2005)
85. M. Mishra, H. Kumar, S. Bajpai, R.K. Singh, K. Tripathi, Level of serum IL-12 and its correlation with endothelial dysfunction, insulin resistance, proinflammatory cytokines and lipid profile in newly diagnosed type 2 diabetes. Diabetes Res. Clin. Pract. 94(2), 255–261 (2011)
86. M.-C. Durpès, C. Morin, J. Paquin-Veillet, R. Beland, M. Paré, M.-O. Guimond et al., PKC- activation inhibits IL-18-binding protein causing endothelial dysfunction and diabetic atherosclerosis. Cardiovasc. Res. 106(2), 303–313 (2015)
87. B. Chandrasekar, W.H. Boylston, K. Venkatachalam, N.J. Webster, S.D. Prabhu, A.J. Valente, Adiponectin blocks interleukin-18-mediated endothelial cell death via APPL1-dependent AMP-activated protein kinase (AMPK) activation and IKK/NF-kappa B/PTEN suppression. J. Biol. Chem. 283(36), 24889–24898 (2008)
88. J.M. Kahlenberg, S.G. Thacker, C.C. Berthier, C.D. Cohen, M. Kretzler, M.J. Kaplan, Inflammasome activation of IL-18 results in endothelial progenitor cell dysfunction in systemic lupus erythematosus. J. Immunol. 187(11), 6143–6156 (2011)
89. X. Zhang, L. Ma, F. Peng, Y. Wu, Y. Chen, L. Yu et al., The endothelial dysfunction in patients with type 2 diabetes mellitus is associated with IL-6 gene promoter polymorphism in Chinese population. Endocrine 40(1), 124–129 (2011)
90. D.Y. Yuen, R.M. Dwyer, V.B. Matthews, L. Zhang, B.G. Drew, B. Neill et al., Interleukin-6 attenuates insulin-mediated increases in endothelial cell signaling but augments skeletal muscle insulin action via differential effects on tumor necrosis factor- expression. Diabetes 58(5), 1086–1095 (2009)
91. F. Andreozzi, E. Laratta, C. Procopio, M.L. Hribal, A. Sciacqua, M. Perticone et al., Interleukin-6 impairs the insulin signaling pathway, promoting production of nitric oxide in human umbilical vein endothelial cells. Mol. Cell. Biol. 27(6), 2372–2383 (2007)
92. Y. Fan, J. Ye, F. Shen, Y. Zhu, Y. Yeghiazarians, W. Zhu et al., Interleukin-6 stimulates circulating blood-derived endothelial progenitor cell angiogenesis in vitro. J. Cereb. Blood Flow Metab. 28(1), 90–98 (2008)
93. Y. Yin, W. Liu, G. Ji, Y. Dai, The essential role of p38 MAPK in mediating the interplay of oxLDL and IL-10 in regulating endothelial cell apoptosis. Eur. J. Cell Biol. 92(4), 150–159 (2013)
94. O. Huet, E. Laemmel, Y. Fu, L. Dupic, A. Aprico, K.L. Andrews et al., Interleukin 10 antioxidant effect decreases leukocytes/endothelial interaction induced by tumor necrosis factor. Shock 39(1), 83–88 (2013)
95. Y. Wang, Q. Chen, Z. Zhang, F. Jiang, X. Meng, H. Yan, Interleukin-10 overexpression improves the function of endothelial progenitor cells stimulated with TNF- through the activation of the STAT3 signaling pathway. Int. J. Mol. Med. 35(2), 471–477 (2015)
96. B.B. Aggarwal, Signalling pathways of the TNF superfamily: a double-edged sword. Nat. Rev. Immunol. 3(9), 745–756 (2003)
97. G. Chen, D.V. Goeddel, TNF-R1 signaling: a beautiful pathway. Science 296(5573), 1634–1635 (2002)
98. B.B. Aggarwal, S.C. Gupta, J.H. Kim, Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey. Blood 119(3), 651–665 (2012)
99. P.J. Naudé, J.A. Boer, P.G. Luiten, U.L. Eisel, Tumor necrosis factor receptor cross-talk. FEBS J. 278(6), 888–898 (2011)
100. N. Makino, T. Maeda, M. Sugano, S. Satoh, R. Watanabe, N. Abe, High serum TNF- level in Type 2 diabetic patients with microangiopathy is associated with eNOS down-regulation and apoptosis in endothelial cells. J. Diabetes Complic. 19(6), 347–355 (2005)
101. K. Zorena, J. Mysliwska, M. Mysliwiec, A. Balcerska, P. Lipowski, K. Raczynska, Relationship between serum levels of tumor necrosis factor-alpha and interleukin-6 in diabetes mellitus type 1 children. Central Eur J Immunol. 32(3), 124 (2007)
102. X. Gao, S. Belmadani, A. Picchi, X. Xu, B.J. Potter, N. Tewari-Singh et al., Tumor necrosis factor- induces endothelial dysfunction in Leprdb mice. Circulation 115(2), 245–254 (2007)
103. H. Zhang, J. Zhang, Z. Ungvari, C. Zhang, Resveratrol improves endothelial function role of TNF and vascular oxidative stress. Arterioscler. Thrombos. Vasc. Biol. 29(8), 1164–1171 (2009)
104. A. Picchi, X. Gao, S. Belmadani, B.J. Potter, M. Focardi, W.M. Chilian et al., Tumor necrosis factor- induces endothelial dysfunction in the prediabetic metabolic syndrome. Circ. Res. 99(1), 69–77 (2006)
105. S. Basuroy, D. Tcheranova, S. Bhattacharya, C.W. Leffler, H. Parfenova, Nox4 NADPH oxidase-derived reactive oxygen species, via endogenous carbon monoxide, promote survival of brain endothelial cells during TNF-induced apoptosis. Am. J. Physiol.-Cell Physiol. 300(2), C256–C265 (2011)
106. H.M. Peshavariya, C.J. Taylor, C. Goh, G.-S. Liu, F. Jiang, E.C. Chan et al., Annexin peptide Ac2-26 suppresses TNF -induced inflammatory responses via inhibition of Rac1-dependent NADPH oxidase in human endothelial cells. PLoS ONE 8(4), e60790 (2013). doi:10.1371/journal.pone.0060790
107. S. Basuroy, S. Bhattacharya, C.W. Leffler, H. Parfenova, Nox4 NADPH oxidase mediates oxidative stress and apoptosis caused by TNF- in cerebral vascular endothelial cells. Am. J. Physiol. Cell Physiol. 296(3), C422–C432 (2009)
108. J.-M. Li, L.M. Fan, M.R. Christie, A.M. Shah, Acute tumor necrosis factor alpha signaling via NADPH oxidase in microvascular endothelial cells: role of p47phox phosphorylation and binding to TRAF4. Mol. Cell. Biol. 25(6), 2320–2330 (2005)
109. J. van Buul, M. Fernandez-Borja, E. Anthony, P. Hordijk, Expression and localization of NOX2 and NOX4 in primary human endothelial cells. Antioxid. Redox Signal. 7(3–4), 308–317 (2005)
110. C. Papaharalambus, W. Sajjad, A. Syed, C. Zhang, M.O. Bergo, R.W. Alexander et al., Tumor necrosis factor alpha stimulation of Rac1 activity. Role of isoprenylcysteine carboxylmethyltransferase. J. Biol. Chem. 280(19), 18790–18796 (2005)
111. D.N. Meijles, L.M. Fan, B.J. Howlin, J.-M. Li, Molecular insights of p47phox phosphorylation dynamics in the regulation of NADPH oxidase activation and superoxide production. J. Biol. Chem. 289(33), 22759–22770 (2014)
112. M. Tesauro, F. Schinzari, V. Rovella, D. Melina, N. Mores, A. Barini et al., Tumor necrosis factor- antagonism improves vasodilation during hyperinsulinemia in metabolic syndrome. Diabetes Care 31(7), 1439–1441 (2008)
113. H. Dominguez, H. Storgaard, C. Rask-Madsen, H.T. Steffen, N. Ihlemann, N.D. Baunbjerg et al., Metabolic and vascular effects of tumor necrosis factor-alpha blockade with etanercept in obese patients with type 2 diabetes. J. Vasc. Res. 42(6), 517–525 (2004)
114. C.V. Desouza, F.G. Hamel, K. Bidasee, K. O’Connell, Role of inflammation and insulin resistance in endothelial progenitor cell dysfunction. Diabetes 60(4), 1286–1294 (2011)
115. T.-G. Chen, Z.-Y. Zhong, G.-F. Sun, Y.-X. Zhou, Y. Zhao, Effects of tumour necrosis factor-alpha on activity and nitric oxide synthase of endothelial progenitor cells from peripheral blood. Cell Prolif. 44(4), 352–359 (2011)
116. A. Hoffmann, D. Baltimore, Circuitry of nuclear factor kappaB signaling. Immunol. Rev. 210, 171–186 (2006)
117. M.S. Hayden, S. Ghosh, Signaling to NF-B. Genes Dev. 18(18), 2195–2224 (2004)
118. A. Bierhaus, S. Schiekofer, M. Schwaninger, M. Andrassy, P.M. Humpert, J. Chen et al., Diabetes-associated sustained activation of the transcription factor nuclear factor-B. Diabetes 50(12), 2792–2808 (2001)
119. Y. Hasegawa, T. Saito, T. Ogihara, Y. Ishigaki, T. Yamada, J. Imai et al., Blockade of the nuclear factor-B pathway in the endothelium prevents insulin resistance and prolongs life spans. Circulation 125(9), 1122–1133 (2012)
120. G.L. Pierce, L.A. Lesniewski, B.R. Lawson, S.D. Beske, D.R. Seals, Nuclear factor-B activation contributes to vascular endothelial dysfunction via oxidative stress in overweight/obese middle-aged and older humans. Circulation 119(9), 1284–1292 (2009)
121. G. Guan, H. Han, Y. Yang, Y. Jin, X. Wang, X. Liu, Neferine prevented hyperglycemia-induced endothelial cell apoptosis through suppressing ROS/Akt/NF-B signal. Endocrine 47(3), 764–771 (2014)
122. S. Brouard, P.O. Berberat, E. Tobiasch, M.P. Seldon, F.H. Bach, M.P. Soares, Heme oxygenase-1-derived carbon monoxide requires the activation of transcription factor NF-B to protect endothelial cells from tumor necrosis factor-mediated apoptosis. J. Biol. Chem. 277(20), 17950–17961 (2002)
123. T. Kisseleva, L. Song, M. Vorontchikhina, N. Feirt, J. Kitajewski, C. Schindler, NF-B regulation of endothelial cell function during LPS-induced toxemia and cancer. J. Clin. Investig. 116(11), 2955 (2006)
124. A. Pfosser, C. El-Aouni, I. Pfisterer, M. Dietz, F. Globisch, G. Stachel et al., NF B activation in embryonic endothelial progenitor cells enhances neovascularization via PSGL-1 mediated recruitment: novel role for LL37. Stem Cells 28(2), 376–385 (2010)
125. K. Ji, C. Xing, F. Jiang, X. Wang, H. Guo, J. Nan et al., Benzo [a] pyrene induces oxidative stress and endothelial progenitor cell dysfunction via the activation of the NF-B pathway. Int. J. Mol. Med. 31(4), 922–930 (2013)
126. S. Parthasarathy, A. Raghavamenon, M.O. Garelnabi, N. Santanam, Oxidized low-density lipoprotein. Free Radic. Antioxid. Protoc. 610, 403–417 (2010)
127. M.T. Marin, P.S. Dasari, J.B. Tryggestad, C.E. Aston, A.M. Teague, K.R. Short, Oxidized HDL and LDL in adolescents with type 2 diabetes compared to normal weight and obese peers. J. Diabetes Complic. 29(5), 679–685 (2015)
128. G. Maiolino, G. Rossitto, P. Caielli, V. Bisogni, G.P. Rossi, L.A. Calò, The role of oxidized low-density lipoproteins in atherosclerosis: the myths and the facts. Mediat. Inflamm. (2013). doi:10.1155/2013/714653
129. J. Galle, R. Schneider, B. Winner, C. Lehmann-Bodem, R. Schinzel, G. Münch et al., Glyc-oxidized LDL impair endothelial function more potently than oxidized LDL: role of enhanced oxidative stress. Atherosclerosis 138(1), 65–77 (1998)
130. Y. Shi, F. Cosentino, G.G. Camici, A. Akhmedov, P.M. Vanhoutte, F.C. Tanner et al., Oxidized low-density lipoprotein activates p66Shc via lectin-like oxidized low-density lipoprotein receptor-1, protein kinase C- and c-Jun N-terminal kinase in human endothelial cells. Arterioscler. Thrombos. Vasc. Biol. 31(9), 2090–2097 (2011)
131. Y. Shi, T.F. Lüscher, G.G. Camici, Dual role of endothelial nitric oxide synthase in oxidized LDL-induced, p66Shc-mediated oxidative stress in cultured human endothelial cells. PLoS ONE 9(9), e107787 (2014). doi:10.1371/journal.pone.0107787
132. K. Yamamoto, A. Kakino, H. Takeshita, N. Hayashi, L. Li, A. Nakano et al. Oxidized LDL (oxLDL) activates the angiotensin II type 1 receptor by binding to the lectin-like oxLDL receptor. FASEB J. fj–15 (2015). doi:10.1096/fj.15-271627
133. C.-S. Chu, Y.-C. Wang, L.-S. Lu, B. Walton, H.R. Yilmaz, R.Y. Huang et al., Electronegative low-density lipoprotein increases C-reactive protein expression in vascular endothelial cells through the LOX-1 receptor. PLoS ONE 8(8), e70533 (2013). doi:10.1371/journal.pone.0070533
134. S. Hamed, B. Brenner, Z. Abassi, A. Aharon, D. Daoud, A. Roguin, Hyperglycemia and oxidized-LDL exert a deleterious effect on endothelial progenitor cell migration in type 2 diabetes mellitus. Thromb. Res. 126(3), 166–174 (2010)
135. T. Imanishi, T. Hano, T. Sawamura, I. Nishio, Oxidized low-density lipoprotein induces endothelial progenitor cell senescence, leading to cellular dysfunction. Clin. Exp. Pharmacol. Physiol. 31(7), 407–413 (2004)
136. K.-T. Ji, L. Qian, J.-L. Nan, Y.-J. Xue, S.-Q. Zhang, G.-Q. Wang et al., Ox-LDL induces dysfunction of endothelial progenitor cells via activation of NF-κB. Biomed. Res. Int. (2015). doi:10.1155/2015/175291
137. F.X. Ma, B. Zhou, Z. Chen, Q. Ren, S.H. Lu, T. Sawamura et al., Oxidized low density lipoprotein impairs endothelial progenitor cells by regulation of endothelial nitric oxide synthase. J. Lipid Res. 47(6), 1227–1237 (2006)
138. B. Shao, J.W. Heinecke, Impact of HDL oxidation by the myeloperoxidase system on sterol efflux by the ABCA1 pathway. J. Proteomics 74(11), 2289–2299 (2011)
139. B. Pan, Y. Ma, H. Ren, Y. He, Y. Wang, X. Lv et al., Diabetic HDL is dysfunctional in stimulating endothelial cell migration and proliferation due to down regulation of SR-BI expression. PLoS ONE 7(11), e48530 (2012). doi:10.1371/journal.pone.0048530
140. A. Undurti, Y. Huang, J.A. Lupica, J.D. Smith, J.A. DiDonato, S.L. Hazen, Modification of high density lipoprotein by myeloperoxidase generates a pro-inflammatory particle. J. Biol. Chem. 284(45), 30825–30835 (2009)
141. T. Matsunaga, S. Hokari, I. Koyama, T. Harada, T. Komoda, NF-B activation in endothelial cells treated with oxidized high-density lipoprotein. Biochem. Biophys. Res. Commun. 303(1), 313–319 (2003)
142. O. Van Oostrom, M. Nieuwdorp, P. Westerweel, I. Hoefer, R. Basser, E. Stroes et al., Reconstituted HDL increases circulating endothelial progenitor cells in patients with type 2 diabetes. Arterioscler. Thrombos. Vasc. Biol. 27(8), 1864–1865 (2007)
143. V. Petoumenos, G. Nickenig, N. Werner, High-density lipoprotein exerts vasculoprotection via endothelial progenitor cells. J. Cell Mol. Med. 13(11–12), 4623–4635 (2009)
144. C.-Y. Huang, F.-Y. Lin, C.-M. Shih, H.-K. Au, Y.-J. Chang, H. Nakagami et al., Moderate to high concentrations of high-density lipoprotein from healthy subjects paradoxically impair human endothelial progenitor cells and related angiogenesis by activating Rho-associated kinase pathways. Arterioscler. Thrombos. Vasc. Biol. 32(10), 2405–2417 (2012)
145. J. Wu, Z. He, X. Gao, F. Wu, R. Ding, Y. Ren et al., Oxidized high-density lipoprotein impairs endothelial progenitor cells’ function by activation of CD36-MAPK-TSP-1 pathways. Antioxid. Redox Signal. 22(4), 308–324 (2015). doi:10.1089/ars.2013.5743
146. C. Schmitz-Peiffer, Targeting ceramide synthesis to reverse insulin resistance. Diabetes 59(10), 2351–2353 (2010)
147. Q.-J. Zhang, W.L. Holland, L. Wilson, J.M. Tanner, D. Kearns, J.M. Cahoon et al., Ceramide mediates vascular dysfunction in diet-induced obesity by PP2A-mediated dephosphorylation of the eNOS-Akt complex. Diabetes 61(7), 1848–1859 (2012)
148. V.C. Mehra, E. Jackson, X.M. Zhang, X.-C. Jiang, L.W. Dobrucki, J. Yu et al., Ceramide-activated phosphatase mediates fatty acid-induced endothelial VEGF resistance and impaired angiogenesis. Am. J. Pathol. 184(5), 1562–1576 (2014)
149. L. Chun, Z. Junlin, W. Aimin, L. Niansheng, C. Benmei, L. Minxiang, Inhibition of ceramide synthesis reverses endothelial dysfunction and atherosclerosis in streptozotocin-induced diabetic rats. Diabetes Res. Clin. Pract. 93(1), 77–85 (2011)
150. D.X. Zhang, A.-P. Zou, P.-L. Li, Ceramide-induced activation of NADPH oxidase and endothelial dysfunction in small coronary arteries. Am. J. Physiol. Heart Circ. Physiol. 284(2), H605–H612 (2003)
151. M. Fu, Z. Li, T. Tan, W. Guo, N. Xie, Q. Liu et al., Akt/eNOS signaling pathway mediates inhibition of endothelial progenitor cells by palmitate-induced ceramide. Am. J. Physiol. Heart Circ. Physiol. 308(1), H11–H17 (2015)
152. P. Zhu, G. Chen, T. You, J. Yao, Q. Jiang, X. Lin et al., High FFA-induced proliferation and apoptosis in human umbilical vein endothelial cell partly through Wnt-catenin signal pathway. Mol. Cell. Biochem. 338(1–2), 123–131 (2010)
153. X.L. Wang, L. Zhang, K. Youker, M.-X. Zhang, J. Wang, S.A. LeMaire et al., Free fatty acids inhibit insulin signaling-stimulated endothelial nitric oxide synthase activation through upregulating PTEN or inhibiting Akt kinase. Diabetes 55(8), 2301–2310 (2006)
154. W.-Y. Zhang, E. Schwartz, Y. Wang, J. Attrep, Z. Li, P. Reaven, Elevated concentrations of nonesterified fatty acids increase monocyte expression of CD11b and adhesion to endothelial cells. Arterioscler. Thromb. Vasc. Biol. 26(3), 514–519 (2006)
155. M. Artwohl, A. Lindenmair, V. Sexl, C. Maier, G. Rainer, A. Freudenthaler et al., Different mechanisms of saturated versus polyunsaturated FFA-induced apoptosis in human endothelial cells. J. Lipid Res. 49(12), 2627–2640 (2008)
156. K. Staiger, H. Staiger, C. Weigert, C. Haas, H.-U. Häring, M. Kellerer, Saturated, but not unsaturated, fatty acids induce apoptosis of human coronary artery endothelial cells via nuclear factor-B activation. Diabetes 55(11), 3121–3126 (2006)
157. Y. Lu, L. Qian, Q. Zhang, B. Chen, L. Gui, D. Huang et al., Palmitate induces apoptosis in mouse aortic endothelial cells and endothelial dysfunction in mice fed high-calorie and high-cholesterol diets. Lifesciences 92(24), 1165–1173 (2013)
158. Z. Gao, H. Zhang, J. Liu, C.W. Lau, P. Liu, Z.Y. Chen et al., Cyclooxygenase-2-dependent oxidative stress mediates palmitate-induced impairment of endothelium-dependent relaxations in mouse arteries. Biochem. Pharmacol. 91(4), 474–482 (2014)
159. Q. Wang, X.-L. Cheng, D.-Y. Zhang, X.-J. Gao, L. Zhou, X.-Y. Qin et al., Tectorigenin attenuates palmitate-induced endothelial insulin resistance via targeting ROS-associated inflammation and IRS-1 pathway. PLoS ONE 8(6), e66417 (2013). doi:10.1371/journal.pone.0066417
160. A. Trombetta, G. Togliatto, A. Rosso, P. Dentelli, C. Olgasi, P. Cotogni et al., Increase of palmitic acid concentration impairs endothelial progenitor cell and bone marrow-derived progenitor cell bioavailability role of the STAT5/PPAR transcriptional complex. Diabetes 62(4), 1245–1257 (2013)
161. W.-X. Guo, Q.-D. Yang, Y.-H. Liu, X.-Y. Xie, M. Wang, R.-C. Niu, Palmitic and linoleic acids impair endothelial progenitor cells by inhibition of Akt/eNOS pathway. Arch. Med. Res. 39(4), 434–442 (2008)
162. X. Gao, H. Zhang, A.M. Schmidt, C. Zhang, AGE/RAGE produces endothelial dysfunction in coronary arterioles in type 2 diabetic mice. Am. J. Physiol. Heart Circ. Physiol. 295(2), H491–H498 (2008)
163. M.-P. Wautier, O. Chappey, S. Corda, D.M. Stern, A.M. Schmidt, J.-L. Wautier, Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. Am. J. Physiol. Endocrinol. Metab. 280(5), E685–E694 (2001)
164. K.-C. Lan, C.-Y. Chiu, C.-W. Kao, K.-H. Huang, C.-C. Wang, K.-T. Huang et al., Advanced glycation end-products induce apoptosis in pancreatic islet endothelial cells via NF-B-activated cyclooxygenase-2/prostaglandin E 2 up-regulation. PLoS ONE 8(6), e66781 (2013). doi:10.1371/journal.pone.0066781
165. S.-J. Yoon, Y.W. Yoon, B.K. Lee, H.M. Kwon, K.-C. Hwang, M. Kim et al., Potential role of HMG CoA reductase inhibitor on oxidative stress induced by advanced glycation endproducts in vascular smooth muscle cells of diabetic vasculopathy. Exp. Mol. Med. 41(11), 802–811 (2009)
166. Y. Ishibashi, T. Matsui, S. Maeda, Y. Higashimoto, S. Yamagishi, Advanced glycation end products evoke endothelial cell damage by stimulating soluble dipeptidyl peptidase-4 production and its interaction with mannose 6-phosphate/insulin-like growth factor II receptor. Cardiovasc Diabetol. 12, 125 (2013)
167. G. Togliatto, A. Trombetta, P. Dentelli, A. Rosso, M. Brizzi, MIR221/MIR222-driven post-transcriptional regulation of P27KIP1 and P57KIP2 is crucial for high-glucose-and AGE-mediated vascular cell damage. Diabetologia 54(7), 1930–1940 (2011)
168. C. Shen, Q. Li, Y. Zhang, G. Ma, Y. Feng, Q. Zhu et al., Advanced glycation endproducts increase EPC apoptosis and decrease nitric oxide release via MAPK pathways. Biomed. Pharmacother. 64(1), 35–43 (2010)
169. J. Chen, M. Song, S. Yu, P. Gao, Y. Yu, H. Wang et al., Advanced glycation endproducts alter functions and promote apoptosis in endothelial progenitor cells through receptor for advanced glycation endproducts mediate overpression of cell oxidant stress. Mol. Cell. Biochem. 335(1–2), 137–146 (2010)
170. Q. Chen, L. Dong, L. Wang, L. Kang, B. Xu, Advanced glycation end products impair function of late endothelial progenitor cells through effects on protein kinase Akt and cyclooxygenase-2. Biochem. Biophys. Res. Commun. 381(2), 192–197 (2009)
171. S. Ueda, S. Yamagishi, T. Matsui, Y. Noda, S. Ueda, Y. Jinnouchi et al., Serum levels of advanced glycation end products (AGEs) are inversely associated with the number and migratory activity of circulating endothelial progenitor cells in apparently healthy subjects. Cardiovasc. Ther. 30(4), 249–254 (2012)
172. H. Li, X. Zhang, X. Guan, X. Cui, Y. Wang, H. Chu et al., Advanced glycation end products impair the migration, adhesion and secretion potentials of late endothelial progenitor cells. Cardiovasc. Diabetol. 11(1), 46 (2012)
173. A.D. Bhatwadekar, J.V. Glenn, G. Li, T.M. Curtis, T.A. Gardiner, A.W. Stitt, Advanced glycation of fibronectin impairs vascular repair by endothelial progenitor cells: implications for vasodegeneration in diabetic retinopathy. Investig. Ophthalmol. Vis. Sci. 49(3), 1232–1241 (2008)
174. S.F. Travis, A.D. Morrison, R.S. Clements, A.I. Winegrad, F.A. Oski, The sorbitol pathway of the human erythrocyte. Pediatr. Res. 4(5), 466 (1970)
175. S.S. Chung, E.C. Ho, K.S. Lam, S.K. Chung, Contribution of polyol pathway to diabetes-induced oxidative stress. J. Am. Soc. Nephrol. 14(suppl 3), S233–S236 (2003)
176. H.M. Cheng, R.G. González, The effect of high glucose and oxidative stress on lens metabolism, aldose reductase, and senile cataractogenesis. Metab., Clin. Exp. 35((4 Suppl 1)), 10–14 (1986)
177. Y.C. Hwang, S. Bakr, C.A. Ellery, P.J. Oates, R. Ramasamy, Sorbitol dehydrogenase: a novel target for adjunctive protection of ischemic myocardium. FASEB J. 17(15), 2331–2333 (2003)
178. J.R. Williamson, K. Chang, M. Frangos, K.S. Hasan, Y. Ido, T. Kawamura et al., Hyperglycemic pseudohypoxia and diabetic complications. Diabetes 42(6), 801–813 (1993)
179. T.J. Guzik, S. Mussa, D. Gastaldi, J. Sadowski, C. Ratnatunga, R. Pillai et al., Mechanisms of increased vascular superoxide production in human diabetes mellitus role of NAD (P) H oxidase and endothelial nitric oxide synthase. Circulation 105(14), 1656–1662 (2002)
180. M. Takeuchi, M. Iwaki, J. Takino, H. Shirai, M. Kawakami, R. Bucala et al., Immunological detection of fructose-derived advanced glycation end-products. Lab. Invest. 90(7), 1117–1127 (2010)
181. S. Lightman, Does aldose reductase have a role in the development of the ocular complications of diabetes? Eye 7(2), 238–241 (1993)
182. S. Yagihashi, S.I. Yamagishi, R. Wada Ri, M. Baba, T.C. Hohman, C. Yabe-Nishimura et al., Neuropathy in diabetic mice overexpressing human aldose reductase and effects of aldose reductase inhibitor. Brain 124((Pt 12)), 2448–2458 (2001)
183. A.M. Gonzalez, M. Sochor, P. McLean, The effect of an aldose reductase inhibitor (sorbinil) on the level of metabolites in lenses of diabetic rats. Diabetes 32(5), 482–485 (1983)
184. M. Mira, M. Azevedo, C. Manso, The neutralization of hydroxyl radical by silibin, sorbinil and bendazac. Free Radic. Res. 4(2), 125–129 (1987)
185. X. Du, T. Matsumura, D. Edelstein, L. Rossetti, Z. Zsengellér, C. Szabó et al., Inhibition of GAPDH activity by poly (ADP-ribose) polymerase activates three major pathways of hyperglycemic damage in endothelial cells. J. Clin. Investig. 112(7), 1049 (2003)
186. P.J. Thornalley, The glyoxalase system: new developments towards functional characterization of a metabolic pathway fundamental to biological life. Biochem. J. 269(1), 1 (1990)
187. D.J. Ceradini, D. Yao, R.H. Grogan, M.J. Callaghan, D. Edelstein, M. Brownlee et al., Decreasing intracellular superoxide corrects defective ischemia-induced new vessel formation in diabetic mice. J. Biol. Chem. 283(16), 10930–10938 (2008)
188. H. Thangarajah, D. Yao, E.I. Chang, Y. Shi, L. Jazayeri, I.N. Vial et al., The molecular basis for impaired hypoxia-induced VEGF expression in diabetic tissues. Proc. Natl. Acad. Sci. U.S.A. 106(32), 13505–13510 (2009)
189. T.-S. Lee, L.C. MacGregor, S.J. Fluharty, G.L. King et al., Differential regulation of protein kinase C and (Na, K)-adenosine triphosphatase activities by elevated glucose levels in retinal capillary endothelial cells. J Clin. Investig. 83(1), 90–94 (1989)
190. T.-S. Lee, K.A. Saltsman, H. Ohashi, G.L. King, Activation of protein kinase C by elevation of glucose concentration: proposal for a mechanism in the development of diabetic vascular complications. Proc. Natl. Acad. Sci. 86(13), 5141–5145 (1989)
191. T. Inoguchi, R. Battan, E. Handler, J.R. Sportsman, W. Heath, G.L. King, Preferential elevation of protein kinase C isoform beta II and diacylglycerol levels in the aorta and heart of diabetic rats: differential reversibility to glycemic control by islet cell transplantation. Proc. Natl. Acad. Sci. 89(22), 11059–11063 (1992)
192. T. Inoguchi, F. Ueda, F. Umeda, T. Yamashita, H. Nawata, Inhibition of intercellular communication via gap junction in cultured aortic endothelial cells by elevated glucose and phorbol ester. Biochem. Biophys. Res. Commun. 208(2), 492–497 (1995)
193. J.J. Lynch, T.J. Ferro, F.A. Blumenstock, A.M. Brockenauer, A.B. Malik, Increased endothelial albumin permeability mediated by protein kinase C activation. J Clin. Invest. 85(6), 1991–1998 (1990)
194. N.S. Harhaj, E.A. Felinski, E.B. Wolpert, J.M. Sundstrom, T.W. Gardner, D.A. Antonetti, VEGF activation of protein kinase C stimulates occludin phosphorylation and contributes to endothelial permeability. Invest. Ophthalmol. Vis. Sci. 47(11), 5106–5115 (2006)
195. F. Cosentino, M. Eto, P. De Paolis, B. van der Loo, M. Bachschmid, V. Ullrich et al., High glucose causes upregulation of cyclooxygenase-2 and alters prostanoid profile in human endothelial cells role of protein kinase C and reactive oxygen species. Circulation 107(7), 1017–1023 (2003)
196. L. Quagliaro, L. Piconi, R. Assaloni, L. Martinelli, E. Motz, A. Ceriello, Intermittent high glucose enhances apoptosis related to oxidative stress in human umbilical vein endothelial cells the role of protein kinase C and NAD (P) H-oxidase activation. Diabetes 52(11), 2795–2804 (2003)
197. P. Geraldes, J. Hiraoka-Yamamoto, M. Matsumoto, A. Clermont, M. Leitges, A. Marette et al., Activation of PKC- and SHP-1 by hyperglycemia causes vascular cell apoptosis and diabetic retinopathy. Nat. Med. 15(11), 1298–1306 (2009)
198. F. Cosentino, P. Francia, G.G. Camici, P.G. Pelicci, M. Volpe, T.F. Lüscher, Final common molecular pathways of aging and cardiovascular disease role of the p66Shc protein. Arterioscler. Thrombos. Vasc. Biol. 28(4), 622–628 (2008)
199. G.M. Pieper et al., Activation of nuclear factor-B in cultured endothelial cells by increased glucose concentration: prevention by calphostin C. J. Cardiovasc. Pharmacol. 30(4), 528–532 (1997)
200. Y. Hou, Y. Wu, S.M. Farooq, X. Guan, S. Wang, Y. Liu et al., A critical role of CXCR2 PDZ-mediated interactions in endothelial progenitor cell homing and angiogenesis. Stem Cell Res. 14(2), 133–143 (2014)
201. M.G. Buse, Hexosamines, insulin resistance, and the complications of diabetes: current status. Am J Physiol Endocrinol Metab. 290(1), E1–E8 (2006)
202. C. Weigert, K. Brodbeck, M. Sawadogo, H.U. Häring, E.D. Schleicher, Upstream stimulatory factor (USF) proteins induce human TGF-1 gene activation via the glucose-response element-1013/-1002 in mesangial cells up-regulation of USF activity by the hexosamine biosynthetic pathway. J. Biol. Chem. 279(16), 15908–15915 (2004)
203. X.-L. Du, D. Edelstein, L. Rossetti, I.G. Fantus, H. Goldberg, F. Ziyadeh et al., Hyperglycemia-induced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing Sp1 glycosylation. Proc. Natl. Acad. Sci. 97(22), 12222–12226 (2000)
204. M. Horal, Z. Zhang, R. Stanton, A. Virkamäki, M.R. Loeken, Activation of the hexosamine pathway causes oxidative stress and abnormal embryo gene expression: involvement in diabetic teratogenesis. Birth Defects Res. A 70(8), 519–527 (2004)
205. B. Musicki, M.F. Kramer, R.E. Becker, A.L. Burnett, Inactivation of phosphorylated endothelial nitric oxide synthase (Ser-1177) by O-GlcNAc in diabetes-associated erectile dysfunction. Proc. Natl. Acad. Sci. U.S.A. 102(33), 11870–11875 (2005)
206. B.L. Trumpower, The protonmotive Q cycle. Energy transduction by coupling of proton translocation to electron transfer by the cytochrome bc1 complex. J. Biol. Chem. 265(20), 11409–11412 (1990)
207. S.S. Korshunov, V.P. Skulachev, A.A. Starkov, High protonic potential actuates a mechanism of production of reactive oxygen species in mitochondria. FEBS Lett. 416(1), 15–18 (1997)
208. M. Brownlee, The pathobiology of diabetic complications a unifying mechanism. Diabetes 54(6), 1615–1625 (2005)
209. X.L. Du, D. Edelstein, S. Dimmeler, Q. Ju, C. Sui, M. Brownlee, Hyperglycemia inhibits endothelial nitric oxide synthase activity by posttranslational modification at the Akt site. J. Clin. Investig. 108(9), 1341 (2001)
210. F. Giacco, M. Brownlee, Oxidative stress and diabetic complications. Circ. Res. 107(9), 1058–1070 (2010)
211. M.-C. Desco, M. Asensi, R. Márquez, J. Martínez-Valls, M. Vento, F.V. Pallardó et al., Xanthine oxidase is involved in free radical production in type 1 diabetes protection by allopurinol. Diabetes 51(4), 1118–1124 (2002)
212. K. Guo, J. Lu, Y. Huang, M. Wu, L. Zhang, H. Yu et al., Protective role of PGC-1 in diabetic nephropathy is associated with the inhibition of ROS through mitochondrial dynamic remodeling. PLoS ONE 10(4), e0125176 (2015). doi:10.1371/journal.pone.0125176
213. E.J. Marrotte, D.-D. Chen, J.S. Hakim, A.F. Chen, Manganese superoxide dismutase expression in endothelial progenitor cells accelerates wound healing in diabetic mice. J. Clin. Investig. 120(12), 4207 (2010)
214. X.-R. Wang, M.-W. Zhang, D.-D. Chen, Y. Zhang, A.F. Chen, AMP-activated protein kinase rescues the angiogenic functions of endothelial progenitor cells via manganese superoxide dismutase induction in type 1 diabetes. Am. J. Physiol.-Endocrinol. Metab. 300(6), E1135–E1145 (2011)
215. V. Di Stefano, C. Cencioni, G. Zaccagnini, A. Magenta, M.C. Capogrossi, F. Martelli, p66ShcA modulates oxidative stress and survival of endothelial progenitor cells in response to high glucose. Cardiovasc. Res. (2009). doi:10.1093/cvr/cvp082
216. B. Antuna-Puente, B. Feve, S. Fellahi, J.-P. Bastard, Adipokines: the missing link between insulin resistance and obesity. Diabetes Metab. 34(1), 2–11 (2008)
217. K. Brochu-Gaudreau, C. Rehfeldt, R. Blouin, V. Bordignon, B.D. Murphy, M.-F. Palin, Adiponectin action from head to toe. Endocrine 37(1), 11–32 (2010)
218. M.I. Saad, M.A. Kamel, M.Y. Hanafi, Modulation of adipocytokines production and serum NEFA level by metformin, glimepiride, and sitagliptin in HFD/STZ diabetic rats. Biochem. Res. Int. (2015). doi:10.1155/2015/138134
219. S.H. Tawfik, B.F. Mahmoud, M.I. Saad, M. Shehata, M.A. Kamel, M.H. Helmy, Similar and additive effects of ovariectomy and diabetes on insulin resistance and lipid metabolism. Biochem. Res. Int. (2015). doi:10.1155/2015/567945
220. S.R. Kashyap, L.J. Roman, L. Mandarino, R. DeFronzo, M. Bajaj, Hypoadiponectinemia is closely associated with impaired nitric oxide synthase activity in skeletal muscle of type 2 diabetic subjects. Metab. Syndr. Rel. Disord. 8(5), 459–463 (2010)
221. M. Ebrahimi-Mamaeghani, S. Mohammadi, S.R. Arefhosseini, P. Fallah, Z. Bazi, Adiponectin as a potential biomarker of vascular disease. Vasc. Health Risk Manag. 11, 55–70 (2015). doi:10.2147/VHRM.S48753
222. K. Tan, A. Xu, W. Chow, M. Lam, V. Ai, S. Tam et al., Hypoadiponectinemia is associated with impaired endothelium-dependent vasodilation. J. Clin. Endocrinol. Metab. 89(2), 765–769 (2004)
223. S. Gustafsson, L. Lind, S. Söderberg, M. Zilmer, J. Hulthe, E. Ingelsson, Oxidative stress and inflammatory markers in relation to circulating levels of adiponectin. Obesity 21(7), 1467–1473 (2013)
224. X. Xiao, Y. Dong, J. Zhong, R. Cao, X. Zhao, G. Wen et al., Adiponectin protects endothelial cells from the damages induced by the intermittent high level of glucose. Endocrine 40(3), 386–393 (2011)
225. A.S. Antonopoulos, M. Margaritis, P. Coutinho, C. Shirodaria, C. Psarros, L. Herdman et al., Adiponectin as a link between type 2 diabetes mellitus and vascular NADPH-oxidase activity in the human arterial wall: the regulatory role of perivascular adipose tissue. Diabetes 64, 2207–2219 (2015). doi:10.2337/db14-1011
226. M. Margaritis, A.S. Antonopoulos, J. Digby, R. Lee, S. Reilly, P. Coutinho et al., Interactions between vascular wall and perivascular adipose tissue reveal novel roles for adiponectin in the regulation of eNOS function in human vessels. Circulation 127, 2209–2221 (2013). doi:10.1161/CIRCULATIONAHA.112.001133
227. X. Wang, H. Pu, C. Ma, T. Jiang, Q. Wei, M. Duan et al., Adiponectin abates atherosclerosis by reducing oxidative stress. Med. Sci. Monit.: Int. Med. J. Exp. Clin. Res. 20, 1792–1800 (2014). doi:10.12659/MSM.892299
228. X. Cai, X. Li, L. Li, X.-Z. Huang, Y.-S. Liu, L. Chen et al., Adiponectin reduces carotid atherosclerotic plaque formation in ApoE-/-mice: roles of oxidative and nitrosative stress and inducible nitric oxide synthase. Mol. Med. Rep. 11(3), 1715–1721 (2015)
229. J. Chang, Y. Li, Y. Huang, K.S. Lam, R.L. Hoo, W.T. Wong et al., Adiponectin prevents diabetic premature senescence of endothelial progenitor cells and promotes endothelial repair by suppressing the p38 MAP kinase/p16INK4A signaling pathway. Diabetes 59(11), 2949–2959 (2010)
230. R. Ouedraogo, X. Wu, S.-Q. Xu, L. Fuchsel, H. Motoshima, K. Mahadev et al., Adiponectin suppression of high-glucose-induced reactive oxygen species in vascular endothelial cells evidence for involvement of a cAMP signaling pathway. Diabetes 55(6), 1840–1846 (2006)
231. Z. Zhi, Z. Pengfei, T. Xiaoyi, M. Genshan, Adiponectin ameliorates angiotensin II-induced vascular endothelial damage. Cell Stress Chaperones 19(5), 705–713 (2014)
232. H. Motoshima, X. Wu, K. Mahadev, B.J. Goldstein, Adiponectin suppresses proliferation and superoxide generation and enhances eNOS activity in endothelial cells treated with oxidized LDL. Biochem. Biophys. Res. Commun. 315(2), 264–271 (2004)
233. S. Plant, B. Shand, P. Elder, R. Scott, Adiponectin attenuates endothelial dysfunction induced by oxidised low-density lipoproteins. Diabetes Vasc. Dis. Res. 5(2), 102–108 (2008)
234. C.-F. Chen, J. Huang, H. Li, C. Zhang, X. Huang, G. Tong et al., MicroRNA-221 regulates endothelial nitric oxide production and inflammatory response by targeting adiponectin receptor 1. Gene 565(2), 246–251 (2015). doi:10.1016/j.gene.2015.04.014
235. A. Xu, P.M. Vanhoutte, Adiponectin and adipocyte fatty acid binding protein in the pathogenesis of cardiovascular disease. Am. J. Physiol. Heart Circ. Physiol. 302(6), H1231–H1240 (2012)
236. V. Lavoie, A.-E. Kernaleguen, G. Charron, N. Farhat, M. Cossette, A.M. Mamarbachi et al., Functional effects of adiponectin on endothelial progenitor cells. Obesity 19(4), 722–728 (2011)
237. S.F. Leicht, T.M. Schwarz, P.C. Hermann, J. Seissler, A. Aicher, C. Heeschen, Adiponectin pretreatment counteracts the detrimental effect of a diabetic environment on endothelial progenitors. Diabetes 60(2), 652–661 (2011)
238. P. Eren, S. Camus, G. Matrone, T.G. Ebrahimian, D. François, A. Tedgui et al., Adiponectinemia controls pro-angiogenic cell therapy. Stem Cells 27(11), 2712–2721 (2009)
239. Y. Matsuo, T. Imanishi, A. Kuroi, H. Kitabata, T. Kubo, Y. Hayashi et al., Effects of plasma adiponectin levels on the number and function of endothelial progenitor cells in patients with coronary artery disease. Circ. J. 71(9), 1376–1382 (2007)
240. X. Zhang, Z. Huang, Y. Xie, X. Chen, J. Zhang, Z. Qiu et al., Lower levels of plasma adiponectin and endothelial progenitor cells are associated with large artery atherosclerotic stroke. Int. J. Neurosci. 0, 1–23 (2014). doi:10.3109/00207454.2014.994624
241. M. Li, J.C. Ho, K.W. Lai, K.K. Au, A. Xu, B.M. Cheung et al., The decrement in circulating endothelial progenitor cells (EPCs) in type 2 diabetes is independent of the severity of the hypoadiponectemia. Diabetes/Metab. Res. Rev. 27(2), 185–194 (2011)
242. C.-Y. Chen, M. Asakura, H. Asanuma, T. Hasegawa, J. Tanaka, N. Toh et al., Plasma adiponectin levels predict cardiovascular events in the observational Arita Cohort Study in Japan: the importance of the plasma adiponectin levels. Hypertens. Res. 35(8), 843–848 (2012)
243. W.T. Wong, X.Y. Tian, A. Xu, J. Yu, C.W. Lau, R.L.C. Hoo et al., Adiponectin is required for PPARγ-mediated improvement of endothelial function in diabetic mice. Cell Metab. 14(1), 104–115 (2011)
244. M.I. Yilmaz, A. Sonmez, K. Caglar, D.E. Gok, T. Eyileten, M. Yenicesu et al., Peroxisome proliferator-activated receptor (PPAR-S) agonist increases plasma adiponectin levels in type 2 diabetic patients with proteinuria. Endocrine 25(3), 207–214 (2004)
245. A.C. Könner, J.C. Brüning, Selective insulin and leptin resistance in metabolic disorders. Cell Metab. 16(2), 144–152 (2012)
246. S. Guzel, A. Seven, A. Kocaoglu, B. Ilk, E.C. Guzel, G.V. Saracoglu et al., Osteoprotegerin, leptin and IL-6: Association with silent myocardial ischemia in type 2 diabetes mellitus. Diabetes Vasc. Dis. Res. 10(1), 25–31 (2013)
247. S.S. Martin, M.J. Blaha, E.D. Muse, A.N. Qasim, M.P. Reilly, R.S. Blumenthal et al., Leptin and incident cardiovascular disease: the multi-ethnic study of atherosclerosis (MESA). Atherosclerosis 239(1), 67–72 (2015)
248. T. Morioka, M. Emoto, Y. Yamazaki, N. Kawano, S. Imamura, R. Numaguchi et al., Leptin is associated with vascular endothelial function in overweight patients with type 2 diabetes. Cardiovasc Diabetol. 13, 10 (2014)
249. T. Kazumi, A. Tsuboi, K. Fukuo, Inverse association of serum leptin with flow-mediated dilatation independent of body fat distribution, insulin resistance, oxidative stress and inflammation in young women. J. Endocrinol. Diabetes Mellit. 2(1), 21–25 (2014)
250. L.M. Biasucci, F. Graziani, V. Rizzello, G. Liuzzo, C. Guidone, A.R. De Caterina et al., Paradoxical preservation of vascular function in severe obesity. Am. J. Med. 123(8), 727–734 (2010)
251. S. Benkhoff, A.E. Loot, I. Pierson, A. Sturza, K. Kohlstedt, I. Fleming et al., Leptin potentiates endothelium-dependent relaxation by inducing endothelial expression of neuronal NO synthase. Arterioscler. Thromb. Vasc. Biol. 32(7), 1605–1612 (2012)
252. A. Jamroz-Wi’sniewska, A. Gertler, G. Solomon, M.E. Wood, M. Whiteman, J. Beltowski, Leptin-induced endothelium-dependent vasorelaxation of peripheral arteries in lean and obese rats: role of nitric oxide and hydrogen sulfide. PLoS ONE 9(1), e86744 (2014). doi:10.1371/journal.pone.0086744
253. M. Korda, R. Kubant, S. Patton, T. Malinski, Leptin-induced endothelial dysfunction in obesity. Am. J. Physiol. Heart Circ. Physiol. 295(4), H1514–H1521 (2008)
254. J.D. Knudson, U.D. Dincer, C. Zhang, A.N. Swafford, R. Koshida, A. Picchi et al., Leptin receptors are expressed in coronary arteries, and hyperleptinemia causes significant coronary endothelial dysfunction. Am. J. Physiol. Heart Circ. Physiol. 289(1), H48–H56 (2005)
255. D. Konukoglu, O. Serin, M.S. Turhan, Plasma leptin and its relationship with lipid peroxidation and nitric oxide in obese female patients with or without hypertension. Arch. Med. Res. 37(5), 602–606 (2006)
256. G. Pandey, M.S. Shihabudeen, H.P. David, E. Thirumurugan, K. Thirumurugan, Association between hyperleptinemia and oxidative stress in obese diabetic subjects. J. Diabetes Metab. Disord. 14(1), 24 (2015)
257. J. Wang, H. Wang, W. Luo, C. Guo, J. Wang, Y.E. Chen et al., Leptin-induced endothelial dysfunction is mediated by sympathetic nervous system activity. J Am Heart Assoc. 2(5), e000299 (2013). doi:10.1161/JAHA.113.000299
258. F. Machleidt, P. Simon, A.F. Krapalis, M. Hallschmid, H. Lehnert, F. Sayk, Experimental hyperleptinemia acutely increases vasoconstrictory sympathetic nerve activity in healthy humans. J. Clin. Endocrinol. Metab. 98(3), E491–E496 (2013)
259. S. Leon-Cabrera, L. Solís-Lozano, K. Suárez-Álvarez, A. González-Chávez, Y.L. Béjar, G. Robles-Díaz et al., Hyperleptinemia is associated with parameters of low-grade systemic inflammation and metabolic dysfunction in obese human beings. Front. Integr. Neurosci. 7, 62 (2013). doi:10.3389/fnint.2013.00062
260. C.J. Hukshorn, J.H.N. Lindeman, K.H. Toet, W.H.M. Saris, P.H.C. Eilers, M.S. Westerterp-Plantenga et al., Leptin and the proinflammatory state associated with human obesity. J. Clin. Endocrinol. Metab. 89(4), 1773–1778 (2004)
261. D. Spruijt-Metz, B. Adar Emken, M.R. Spruijt, J.M. Richey, L.J. Berman, B.R. Belcher et al., CRP is related to higher leptin levels in minority peripubertal females regardless of adiposity levels. Obesity 20(3), 512–516 (2012)
262. P. Jitprasertwong, K.M. Jaedicke, C.J. Nile, P.M. Preshaw, J.J. Taylor, Leptin enhances the secretion of interleukin (IL)-18, but not IL-1β, from human monocytes via activation of caspase-1. Cytokine 65(2), 222–230 (2014)
263. M.R. Indra, S. Karyono, R. Ratnawati, S.G. Malik, Quercetin suppresses inflammation by reducing ERK1/2 phosphorylation and NF kappa B activation in leptin-induced human umbilical vein endothelial cells (HUVECs). BMC Res. Notes 6(1), 275 (2013)
264. R. Wolk, A. Deb, N.M. Caplice, V.K. Somers, Leptin receptor and functional effects of leptin in human endothelial progenitor cells. Atherosclerosis 183(1), 131–139 (2005)
265. M.R. Schroeter, M. Leifheit, P. Sudholt, N.-M. Heida, C. Dellas, I. Rohm et al., Leptin enhances the recruitment of endothelial progenitor cells into neointimal lesions after vascular injury by promoting integrin-mediated adhesion. Circ. Res. 103(5), 536–544 (2008)
266. M.R. Schroeter, S. Stein, N.-M. Heida, M. Leifheit-Nestler, I.-F. Cheng, R. Gogiraju et al., Leptin promotes the mobilization of vascular progenitor cells and neovascularization by NOX2-mediated activation of MMP9. Cardiovasc. Res. (2011). doi:10.1093/cvr/cvr275
267. K.M. Utzschneider, D.B. Carr, J. Tong, T.M. Wallace, R.L. Hull, S. Zraika et al., Resistin is not associated with insulin sensitivity or the metabolic syndrome in humans. Diabetologia 48(11), 2330–2333 (2005)
268. G. Hasegawa, M. Ohta, Y. Ichida, H. Obayashi, M. Shigeta, M. Yamasaki et al., Increased serum resistin levels in patients with type 2 diabetes are not linked with markers of insulin resistance and adiposity. Acta Diabetol. 42(2), 104–109 (2005)
269. G. Hoefle, C.H. Saely, L. Risch, L. Koch, F. Schmid, P. Rein et al., Relationship between the adipose-tissue hormone resistin and coronary artery disease. Clin. Chim. Acta 386(1), 1–6 (2007)
270. H. Ye, H.J. Zhang, A. Xu, R.L.C. Hoo, Resistin production from adipose tissue is decreased in db/db obese mice, and is reversed by rosiglitazone. PLoS ONE 8(6), e65543 (2013). doi:10.1371/journal.pone.0065543
271. H. Raff, E.D. Bruder, Adiponectin and resistin in the neonatal rat. Endocrine 29(2), 341–344 (2006)
272. Z. Luo, Y. Zhang, F. Li, J. He, H. Ding, L. Yan et al., Resistin induces insulin resistance by both AMPK-dependent and AMPK-independent mechanisms in HepG2 cells. Endocrine 36(1), 60–69 (2009)
273. B.H. Chen, Y. Song, E.L. Ding, C.K. Roberts, J.E. Manson, N. Rifai et al., Circulating levels of resistin and risk of type 2 diabetes in men and women: results from two prospective cohorts. Diabetes Care 32(2), 329–334 (2009)
274. Y. Takata, H. Osawa, M. Kurata, M. Kurokawa, J. Yamauchi, M. Ochi et al., Hyperresistinemia is associated with coexistence of hypertension and type 2 diabetes. Hypertension 51(2), 534–539 (2008)
275. C. Menzaghi, S. Bacci, L. Salvemini, C. Mendonca, G. Palladino, A. Fontana et al., Serum resistin, cardiovascular disease and all-cause mortality in patients with type 2 diabetes. PLoS ONE 8(6), e64729 (2013). doi:10.1371/journal.pone.0064729
276. E.D. Muse, D.I. Feldman, M.J. Blaha, Z.A. Dardari, R.S. Blumenthal, M.J. Budoff et al., The association of resistin with cardiovascular disease in the multi-ethnic study of atherosclerosis. Atherosclerosis. 239(1), 101–108 (2015)
277. G. Lupattelli, S. Marchesi, T. Ronti, R. Lombardini, S. Bruscoli, R. Bianchini et al., Endothelial dysfunction in vivo is related to monocyte resistin mRNA expression. J. Clin. Pharm. Ther. 32(4), 373–379 (2007)
278. G.M. Dick, P.S. Katz, M. Farias, M. Morris, J. James, J.D. Knudson et al., Resistin impairs endothelium-dependent dilation to bradykinin, but not acetylcholine, in the coronary circulation. Am. J. Physiol. Heart Circ. Physiol. 291(6), H2997–H3002 (2006)
279. M.T. Gentile, C. Vecchione, G. Marino, A. Aretini, A. Di Pardo, G. Antenucci et al., Resistin impairs insulin-evoked vasodilation. Diabetes 57(3), 577–583 (2008)
280. C. Chen, J. Jiang, J.-M. Lü, H. Chai, X. Wang, P.H. Lin et al., Resistin decreases expression of endothelial nitric oxide synthase through oxidative stress in human coronary artery endothelial cells. Am. J. Physiol. Heart Circ. Physiol. 299(1), H193–H201 (2010)
281. M.S. Jamaluddin, S. Yan, J. Lü, Z. Liang, Q. Yao, C. Chen, Resistin increases monolayer permeability of human coronary artery endothelial cells. PLoS ONE 8(12), e84576 (2013). doi:10.1371/journal.pone.0084576
282. Y. Li, Y. Wang, Q. Li, Y. Chen, S. Sun, W. Zhang et al., Effect of resistin on vascular endothelium secretion dysfunction in rats. Endothelium 14(4–5), 207–214 (2007)
283. P. Codoñer-Franch, S. Tavárez-Alonso, M. Porcar-Almela, M. Navarro-Solera, Á. Arilla-Codoñer, E. Alonso-Iglesias, Plasma resistin levels are associated with homocysteine, endothelial activation, and nitrosative stress in obese youths. Clin. Biochem. 47(1–2), 44–48 (2014)
284. J.J. Lozano-Nuevo, T. Estrada-Garcia, H. Vargas-Robles, B.A. Escalante-Acosta, A.F. Rubio-Guerra, Correlation between circulating adhesion molecules and resistin levels in hypertensive type-2 diabetic patients. Inflamm. Allergy Drug Targets 10(1), 27–31 (2011)
285. N. Al-Daghri, R. Chetty, P.G. McTernan, K. Al-Rubean, O. Al-Attas, A. Jones et al., Serum resistin is associated with C-reactive protein and LDL-cholesterol in type 2 diabetes and coronary artery disease in a Saudi population. Cardiovasc. Diabetol. 4(1), 10 (2005)
286. C. Ying, L. Sui-xin, X. Kang-ling, Z. Wen-liang, D. Lei, L. Yuan et al., MicroRNA-492 reverses high glucose-induced insulin resistance in huvec cells through targeting resistin. Mol. Cell. Biochem. 391(1–2), 117–125 (2014)
287. J.R. Revollo, A. Körner, K.F. Mills, A. Satoh, T. Wang, A. Garten et al., Nampt/PBEF/Visfatin regulates insulin secretion in beta cells as a systemic NAD biosynthetic enzyme. Cell Metab. 6(5), 363–375 (2007)
288. D. Friebe, M. Neef, J. Kratzsch, S. Erbs, K. Dittrich, A. Garten et al., Leucocytes are a major source of circulating nicotinamide phosphoribosyltransferase (NAMPT)/pre-B cell colony (PBEF)/visfatin linking obesity and inflammation in humans. Diabetologia 54(5), 1200–1211 (2011)
289. K. Krzyzanowska, W. Krugluger, F. Mittermayer, R. Rahman, D. Haider, N. Shnawa et al., Increased visfatin concentrations in women with gestational diabetes mellitus. Clin. Sci. 110, 605–609 (2006)
290. Y.-H. Chang, D.-M. Chang, K.-C. Lin, S.-J. Shin, Y.-J. Lee, Visfatin in overweight/obesity, type 2 diabetes mellitus, insulin resistance, metabolic syndrome and cardiovascular diseases: a meta-analysis and systemic review. Diabetes/Metab. Res. Rev. 27(6), 515–527 (2011)
291. T.-F. Chan, Y.-L. Chen, C.-H. Lee, F.-H. Chou, L.-C. Wu, S.-B. Jong et al., Decreased plasma visfatin concentrations in women with gestational diabetes mellitus. J. Soc. Gynecol. Investig. 13(5), 364–367 (2006)
292. P. Wang, M.M.J. van Greevenbroek, F.G. Bouwman, M.C.G.J. Brouwers, C.J.H. van der Kallen, E. Smit et al., The circulating PBEF/NAMPT/visfatin level is associated with a beneficial blood lipid profile. Pflugers Arch. 454(6), 971–976 (2007)
293. K. Takebayashi, M. Suetsugu, S. Wakabayashi, Y. Aso, T. Inukai, Association between plasma visfatin and vascular endothelial function in patients with type 2 diabetes mellitus. Metabolism 56(4), 451–458 (2007)
294. A. Kamińska, E. Kopczyńska, M. Bieliński, A. Borkowska, R. Junik, Visfatin concentrations in obese patients in relation to the presence of newly diagnosed glucose metabolism disorders. Endokrynol. Polska. 66(2), 108–113 (2015)
295. K. Oki, K. Yamane, N. Kamei, H. Nojima, N. Kohno, Circulating visfatin level is correlated with inflammation, but not with insulin resistance. Clin. Endocrinol. 67(5), 796–800 (2007)
296. Y.-C. Chang, T.-J. Chang, W.-J. Lee, L.-M. Chuang, The relationship of visfatin/pre-B-cell colony-enhancing factor/nicotinamide phosphoribosyltransferase in adipose tissue with inflammation, insulin resistance, and plasma lipids. Metabolism 59(1), 93–99 (2010)
297. Y.S. Kang, H.K. Song, M.H. Lee, G.J. Ko, D.R. Cha, Plasma concentration of visfatin is a new surrogate marker of systemic inflammation in type 2 diabetic patients. Diabetes Res. Clin. Pract. 89(2), 141–149 (2010)
298. W. Lee, C. Wu, H. Lin, I. Lee, C. Wu, J. Tseng et al., Visfatin-induced expression of inflammatory mediators in human endothelial cells through the NF-B pathway. Int. J. Obes. 33(4), 465–472 (2009)
299. S.-R. Kim, Y.-H. Bae, S.-K. Bae, K.-S. Choi, K.-H. Yoon, T.H. Koo et al., Visfatin enhances ICAM-1 and VCAM-1 expression through ROS-dependent NF-kappaB activation in endothelial cells. Biochim. Biophys. Acta 1783(5), 886–895 (2008)
300. T. Romacho, L.A. Villalobos, E. Cercas, R. Carraro, C.F. Sánchez-Ferrer, C. Peiró, Visfatin as a novel mediator released by inflamed human endothelial cells. PLoS ONE 8(10), e78283 (2013). doi:10.1371/journal.pone.0078283
301. P. Saddi-Rosa, C. Oliveira, F. Crispim, F. Giuffrida, V. De Lima, J. Vieira et al., Association of circulating levels of nicotinamide phosphoribosyltransferase (NAMPT/Visfatin) and of a frequent polymorphism in the promoter of the NAMPT gene with coronary artery disease in diabetic and non-diabetic subjects. Cardiovasc. Diabetol. 12(1), 119 (2013)
302. R. Adya, B.K. Tan, J. Chen, H.S. Randeva, Nuclear factor-B induction by visfatin in human vascular endothelial cells its role in MMP-2/9 production and activation. Diabetes Care 31(4), 758–760 (2008)
303. T. Romacho, V. Azcutia, M. Vazquez-Bella, N. Matesanz, E. Cercas, J. Nevado et al., Extracellular PBEF/NAMPT/visfatin activates pro-inflammatory signalling in human vascular smooth muscle cells through nicotinamide phosphoribosyltransferase activity. Diabetologia 52(11), 2455–2463 (2009)
304. M. Xia, C. Zhang, K.M. Boini, A.M. Thacker, P.-L. Li, Membrane raft-lysosome redox signaling platforms in coronary endothelial dysfunction induced by adipokine visfatin. Cardiovasc. Res. (2010). doi:10.1093/cvr/cvq286
305. S. Vallejo, T. Romacho, J. Angulo, L.A. Villalobos, E. Cercas, A. Leivas et al., Visfatin impairs endothelium-dependent relaxation in rat and human mesenteric microvessels through nicotinamide phosphoribosyltransferase activity. PLoS ONE 6(11), e27299 (2011). doi:10.1371/journal.pone.0027299
306. L.A. Villalobos, A. Uryga, T. Romacho, A. Leivas, C.F. Sánchez-Ferrer, J.D. Erusalimsky et al., Visfatin/Nampt induces telomere damage and senescence in human endothelial cells. Int. J. Cardiol. 175(3), 573–575 (2014)
307. Ö.F. Karataş, M. Yıldırım, H. Celik, H. Badem, M. Çaviş, E. Çimentepe, The association between plasma visfatin levels and ED. Int. J. Impot. Res. 27(4), 157–160 (2015). doi:10.1038/ijir.2015.1
308. N.M. Borradaile, J.G. Pickering, Nicotinamide phosphoribosyltransferase imparts human endothelial cells with extended replicative lifespan and enhanced angiogenic capacity in a high glucose environment. Aging Cell 8(2), 100–112 (2009)
309. F. Lovren, Y. Pan, P.C. Shukla, A. Quan, H. Teoh, P.E. Szmitko et al., Visfatin activates eNOS via Akt and MAP kinases and improves endothelial cell function and angiogenesis in vitro and in vivo: translational implications for atherosclerosis. Am. J. Physiol. Endocrinol. Metab. 296(6), E1440–E1449 (2009)
310. H. Yamawaki, N. Hara, M. Okada, Y. Hara, Visfatin causes endothelium-dependent relaxation in isolated blood vessels. Biochem. Biophys. Res. Commun. 383(4), 503–508 (2009)
311. S. Chen, L. Sun, H. Gao, L. Ren, N. Liu, G. Song, Visfatin and oxidative stress influence endothelial progenitor cells in obese populations. Endocr. Res. 40, 1–5 (2014)
312. Y. Sun, S. Chen, G. Song, L. Ren, L. Wei, N. Liu et al., Effect of visfatin on the function of endothelial progenitor cells in high-fat-fed obese rats and investigation of its mechanism of action. Int. J. Mol. Med. 30(3), 622–628 (2012)
313. J.-Y. Zhou, L. Chan, S.-W. Zhou, Omentin: linking metabolic syndrome and cardiovascular disease. Curr. Vasc. Pharmacol. 12(1), 136–143 (2014)
314. H.J. Yoo, S.Y. Hwang, H.C. Hong, H.Y. Choi, S.J. Yang, K.W. Lee et al., Implication of circulating omentin-1 level on the arterial stiffening in type 2 diabetes mellitus. Endocrine 44(3), 680–687 (2013)
315. L. Brunetti, S. Leone, G. Orlando, C. Ferrante, L. Recinella, A. Chiavaroli et al., Hypotensive effects of omentin-1 related to increased adiponectin and decreased interleukin-6 in intra-thoracic pericardial adipose tissue. Pharmacol. Rep. 66(6), 991–995 (2014)
316. J.M. Moreno-Navarrete, F. Ortega, A. Castro, M. Sabater, W. Ricart, J.M. Fernández-Real, Circulating omentin as a novel biomarker of endothelial dysfunction. Obesity 19(8), 1552–1559 (2011)
317. S. Maruyama, R. Shibata, R. Kikuchi, Y. Izumiya, T. Rokutanda, S. Araki et al., Fat-derived factor omentin stimulates endothelial cell function and ischemia-induced revascularization via endothelial nitric oxide synthase-dependent mechanism. J. Biol. Chem. 287(1), 408–417 (2012)
318. H. Yamawaki, J. Kuramoto, S. Kameshima, T. Usui, M. Okada, Y. Hara, Omentin, a novel adipocytokine inhibits TNF-induced vascular inflammation in human endothelial cells. Biochem. Biophys. Res. Commun. 408(2), 339–343 (2011)
319. X. Zhong, X. Li, F. Liu, H. Tan, D. Shang, Omentin inhibits TNF-α-induced expression of adhesion molecules in endothelial cells via ERK/NF-κB pathway. Biochem. Biophys. Res. Commun. 425(2), 401–406 (2012)
320. M. Blüher, Vaspin in obesity and diabetes: pathophysiological and clinical significance. Endocrine 41(2), 176–182 (2012)
321. C.H. Jung, W.J. Lee, J.Y. Hwang, M.J. Lee, S.M. Seol, Y.M. Kim et al., Vaspin increases nitric oxide bioavailability through the reduction of asymmetric dimethylarginine in vascular endothelial cells. PLoS ONE 7(12), e52346 (2012). doi:10.1371/journal.pone.0052346
322. C.H. Jung, W.J. Lee, J.Y. Hwang, S.M. Seol, Y.M. Kim, Y. La Lee et al., Vaspin protects vascular endothelial cells against free fatty acid-induced apoptosis through a phosphatidylinositol 3-kinase/Akt pathway. Biochem. Biophys. Res. Commun. 413(2), 264–269 (2011)
323. S. Phalitakul, M. Okada, Y. Hara, H. Yamawaki, Vaspin prevents methylglyoxal-induced apoptosis in human vascular endothelial cells by inhibiting reactive oxygen species generation. Acta Physiol. 209(3), 212–219 (2013)
324. B.-D. Fu, H. Yamawaki, M. Okada, Y. Hara, Vaspin can not inhibit TNF-alpha-induced inflammation of human umbilical vein endothelial cells. J. Vet. Med. Sci. 71(9), 1201–1207 (2009)
325. C.H. Jung, M.J. Lee, Y.M. Kang, Y.L. Lee, H.K. Yoon, S.-W. Kang et al., Vaspin inhibits cytokine-induced nuclear factor-kappa B activation and adhesion molecule expression via AMP-activated protein kinase activation in vascular endothelial cells. Cardiovasc. Diabetol. 13, 41 (2014)
326. S. Liu, Y. Dong, T. Wang, S. Zhao, K. Yang, X. Chen et al., Vaspin inhibited proinflammatory cytokine induced activation of nuclear factor-kappa B and its downstream molecules in human endothelial EA. hy926 cells. Diabetes Res. Clin. Pract. 103(3), 482–488 (2014)
327. N. Sun, H. Wang, L. Wang, Vaspin alleviates dysfunction of endothelial progenitor cells induced by high glucose via PI3K/Akt/eNOS pathway. Int. J. Clin. Exp. Pathol. 8(1), 482 (2015)
328. I. Jialal, S. Devaraj, H. Kaur, B. Adams-Huet, A.A. Bremer, Increased chemerin and decreased omentin-1 in both adipose tissue and plasma in nascent metabolic syndrome. J. Clin. Endocrinol. Metab. 98(3), E514–E517 (2013)
329. A.A. Roman, S.D. Parlee, C.J. Sinal, Chemerin: a potential endocrine link between obesity and type 2 diabetes. Endocrine 42(2), 243–251 (2012)
330. P. Fülöp, I. Seres, H. Lőrincz, M. Harangi, S. Somodi, G. Paragh, Association of chemerin with oxidative stress, inflammation and classical adipokines in non-diabetic obese patients. J. Cell Mol. Med. 18(7), 1313–1320 (2014)
331. Q. Yan, Y. Zhang, J. Hong, W. Gu, M. Dai, J. Shi et al., The association of serum chemerin level with risk of coronary artery disease in Chinese adults. Endocrine 41(2), 281–288 (2012)
332. W. Hu, Q. Yu, J. Zhang, D. Liu, Rosiglitazone ameliorates diabetic nephropathy by reducing the expression of chemerin and ChemR23 in the kidney of streptozotocin-induced diabetic rats. Inflammation 35(4), 1287–1293 (2012)
333. N.S. Lobato, K.B. Neves, F.P. Filgueira, Z.B. Fortes, M.H.C. Carvalho, R.C. Webb et al., The adipokine chemerin augments vascular reactivity to contractile stimuli via activation of the MEK-ERK1/2 pathway. Life Science 91(13–14), 600–606 (2012)
334. K.B. Neves, N.S. Lobato, R.A.M. Lopes, F.P. Filgueira, C.Z. Zanotto, A.M. Oliveira et al., Chemerin reduces vascular nitric oxide/cGMP signalling in rat aorta: a link to vascular dysfunction in obesity? Clin. Sci. 127(2), 111–122 (2014)
335. L. Wang, T. Yang, Y. Ding, Y. Zhong, L. Yu, M. Peng, Chemerin plays a protective role by regulating human umbilical vein endothelial cell-induced nitric oxide signaling in preeclampsia. Endocrine 48(1), 299–308 (2015)
336. W. Shen, C. Tian, H. Chen, Y. Yang, D. Zhu, P. Gao et al., Oxidative stress mediates chemerin-induced autophagy in endothelial cells. Free Radic. Biol. Med. 55, 73–82 (2013)
337. J. Weigert, M. Neumeier, J. Wanninger, M. Filarsky, S. Bauer, R. Wiest et al., Systemic chemerin is related to inflammation rather than obesity in type 2 diabetes. Clin. Endocrinol. 72(3), 342–348 (2010)
338. H. Yamawaki, S. Kameshima, T. Usui, M. Okada, Y. Hara, A novel adipocytokine, chemerin exerts anti-inflammatory roles in human vascular endothelial cells. Biochem. Biophys. Res. Commun. 423(1), 152–157 (2012)
339. I. Castan-Laurell, C. Dray, C. Attané, T. Duparc, C. Knauf, P. Valet, Apelin, diabetes, and obesity. Endocrine 40(1), 1–9 (2011)
340. A.G. Japp, N.L. Cruden, D.A. Amer, V.K. Li, E.B. Goudie, N.R. Johnston et al., Vascular effects of apelin in vivo in man. J. Am. Coll. Cardiol. 52(11), 908–913 (2008)
341. J.-C. Zhong, X.-Y. Yu, Y. Huang, L.-M. Yung, C.-W. Lau, S.-G. Lin, Apelin modulates aortic vascular tone via endothelial nitric oxide synthase phosphorylation pathway in diabetic mice. Cardiovasc. Res. 74(3), 388–395 (2007)
342. Y.-C. Liao, Y.-S. Wang, E. Hsi, M.-H. Chang, Y.-Z. You, S.-H.H. Juo, MicroRNA-765 influences arterial stiffness through modulating apelin expression. Mol. Cell. Endocrinol. 411, 11–19 (2015). doi:10.1016/j.mce.2015.04.006
343. K. Nagano, J. Ishida, M. Unno, T. Matsukura, A. Fukamizu, Apelin elevates blood pressure in ICR mice with L-NAME-induced endothelial dysfunction. Mol. Med. Rep. 7(5), 1371–1375 (2013)
344. Y. Lu, X. Zhu, G.-X. Liang, R.-R. Cui, Y. Liu, S.-S. Wu et al., Apelin-APJ induces ICAM-1, VCAM-1 and MCP-1 expression via NF-κB/JNK signal pathway in human umbilical vein endothelial cells. Amino Acids 43(5), 2125–2136 (2012)
345. D.J. Drucker, M.A. Nauck, The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368(9548), 1696–1705 (2006)
346. S. Ravassa, J. Beaumont, A. Huerta, J. Barba, I. Coma-Canella, A. González et al., Association of low GLP-1 with oxidative stress is related to cardiac disease and outcome in patients with type 2 diabetes mellitus: a pilot study. Free Radic. Biol. Med. (2015). doi:10.1016/j.freeradbiomed.2015.01.002
347. B. Gallwitz, Extra-pancreatic effects of incretin-based therapies. Endocrine 47(2), 360–371 (2014)
348. A. Ceriello, A. Novials, E. Ortega, S. Canivell, L. La Sala, G. Pujadas et al., Glucagon-like peptide 1 reduces endothelial dysfunction, inflammation, and oxidative stress induced by both hyperglycemia and hypoglycemia in type 1 diabetes. Diabetes Care 36(8), 2346–2350 (2013)
349. P.C. Van Poppel, M.G. Netea, P. Smits, C.J. Tack, Vildagliptin improves endothelium-dependent vasodilatation in type 2 diabetes. Diabetes Care 34(9), 2072–2077 (2011)
350. A. Ceriello, L. La Sala, V. De Nigris, G. Pujadas, R. Testa, A. Uccellatore et al., GLP-1 reduces metalloproteinase-14 and soluble endoglin induced by both hyperglycemia and hypoglycemia in type 1 diabetes. Endocrine. 2015;1–4. doi:10.1007/s12020-015-0565-2
351. Y. Noda, T. Miyoshi, H. Oe, Y. Ohno, K. Nakamura, N. Toh et al., Alogliptin ameliorates postprandial lipemia and postprandial endothelial dysfunction in non-diabetic subjects: a preliminary report. Cardiovasc. Diabetol. 12(8), 8–12 (2013)
352. J. Koska, M. Sands, C. Burciu, K.M. D’Souza, K. Raravikar, J. Liu et al., Exenatide protects against glucose and lipid-induced endothelial dysfunction: evidence for direct vasodilation effect of GLP-1 receptor agonists in humans. Diabetes (2015). doi:10.2337/db14-0976
353. R. Faber, M. Zander, A. Pena, M.M. Michelsen, N.D. Mygind, E. Prescott, Effect of the glucagon-like peptide-1 analogue liraglutide on coronary microvascular function in patients with type 2 diabetes-a randomized, single-blinded, cross-over pilot study. Cardiovasc. Diabetol. 14(1), 41 (2015)
354. L. Ding, J. Zhang, Glucagon-like peptide-1 activates endothelial nitric oxide synthase in human umbilical vein endothelial cells. Acta Pharmacol. Sin. 33(1), 75–81 (2012)
355. Z. Dong, W. Chai, W. Wang, L. Zhao, Z. Fu, W. Cao et al., Protein kinase A mediates glucagon-like peptide 1-induced nitric oxide production and muscle microvascular recruitment. Am. J. Physiol. Endocrinol. Metab. 304(2), E222–E228 (2013)
356. H. Liu, Y. Hu, R.W. Simpson, A.E. Dear, Glucagon-like peptide-1 attenuates tumour necrosis factor-alpha-mediated induction of plasminogen [corrected] activator inhibitor-1 expression. J. Endocrinol. 196(1), 57–65 (2008)
357. H. Liu, A.E. Dear, L.B. Knudsen, R.W. Simpson, A long-acting glucagon-like peptide-1 analogue attenuates induction of plasminogen activator inhibitor type-1 and vascular adhesion molecules. J. Endocrinol. 201(1), 59–66 (2009)
358. N.M. Krasner, Y. Ido, N.B. Ruderman, J.M. Cacicedo, Glucagon-like peptide-1 (GLP-1) analog liraglutide inhibits endothelial cell inflammation through a calcium and AMPK dependent mechanism. PLoS ONE 9(5), e97554 (2014). doi:10.1371/journal.pone.0097554
359. H. Oeseburg, R.A. de Boer, H. Buikema, P. van der Harst, W.H. van Gilst, H.H. Silljé, Glucagon-like peptide 1 prevents reactive oxygen species-induced endothelial cell senescence through the activation of protein kinase A. Arterioscler. Thromb. Vasc. Biol. 30(7), 1407–1414 (2010)
360. Y. Zhan, H. Sun, H. Chen, H. Zhang, J. Sun, Z. Zhang et al., Glucagon-like peptide-1 (GLP-1) protects vascular endothelial cells against advanced glycation end products (AGEs)-induced apoptosis. Ann. Transpl. 18(7), BR286–BR291 (2012)
361. Y. Ishibashi, T. Matsui, M. Takeuchi, S. Yamagishi, Glucagon-like peptide-1 (GLP-1) inhibits advanced glycation end product (AGE)-induced up-regulation of VCAM-1 mRNA levels in endothelial cells by suppressing AGE receptor (RAGE) expression. Biochem. Biophys. Res. Commun. 391(3), 1405–1408 (2010)
362. F. Liu, X. Zhang, L. Gong, X. Wang, J. Wang, X. Hou et al., Glucagon-like peptide 1 protects microvascular endothelial cells by inactivating the PARP-1/iNOS/NO pathway. Mol. Cell. Endocrinol. 339(1–2), 25–33 (2011)
363. S. Salheen, U. Panchapakesan, C. Pollock, O. Woodman, The DPP-4 inhibitor linagliptin and the GLP-1 receptor agonist exendin-4 improve endothelium-dependent relaxation of rat mesenteric arteries in the presence of high glucose. Pharmacol. Res. 94, 26–33 (2015)
364. B. Batchuluun, T. Inoguchi, N. Sonoda, S. Sasaki, T. Inoue, Y. Fujimura et al., Metformin and liraglutide ameliorate high glucose-induced oxidative stress via inhibition of PKC-NAD (P) H oxidase pathway in human aortic endothelial cells. Atherosclerosis 232(1), 156–164 (2014)
365. B. Schisano, A.L. Harte, K. Lois, P. Saravanan, N. Al-Daghri, O. Al-Attas et al., GLP-1 analogue, Liraglutide protects human umbilical vein endothelial cells against high glucose induced endoplasmic reticulum stress. Regul. Pept. 174(1), 46–52 (2012)
366. X. Xiao-Yun, M. Zhao-Hui, C. Ke, H. Hong-Hui, X. Yan-Hong, Glucagon-like peptide-1 improves proliferation and differentiation of endothelial progenitor cells via upregulating VEGF generation. Ann. Transpl. 17(2), BR35–BR41 (2011)
367. G.P. Fadini, E. Boscaro, M. Albiero, L. Menegazzo, V. Frison, S. De Kreutzenberg et al., The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes possible role of stromal-derived factor-1. Diabetes Care 33(7), 1607–1609 (2010)
368. C.-Y. Huang, C.-M. Shih, N.-W. Tsao, Y.-W. Lin, P.-H. Huang, S.-C. Wu et al., Dipeptidyl peptidase-4 inhibitor improves neovascularization by increasing circulating endothelial progenitor cells. Br. J. Pharmacol. 167(7), 1506–1519 (2012)
369. L. Pulkkinen, O. Ukkola, M. Kolehmainen, M. Uusitupa, Ghrelin in diabetes and metabolic syndrome. Int. J. Pept. (2010). doi:10.1155/2010/248948
370. D. Perez-Tilve, R. Nogueiras, F. Mallo, S.C. Benoit, M. Tschoep, Gut hormones ghrelin, PYY, and GLP-1 in the regulation of energy, balance and metabolism. Endocrine 29(1), 61–71 (2006)
371. M. Suematsu, A. Katsuki, Y. Sumida, E.C. Gabazza, S. Murashima, K. Matsumoto et al., Decreased circulating levels of active ghrelin are associated with increased oxidative stress in obese subjects. Eur. J. Endocrinol. 153(3), 403–407 (2005)
372. O. Gruzdeva, E. Uchasova, E. Belik, Y. Dyleva, E. Shurygina, O. Barbarash, Lipid, adipokine and ghrelin levels in myocardial infarction patients with insulin resistance. BMC Cardiovasc. Disord. 14(1), 7 (2014)
373. M. Tesauro, F. Schinzari, M. Iantorno, S. Rizza, D. Melina, D. Lauro et al., Ghrelin improves endothelial function in patients with metabolic syndrome. Circulation 112(19), 2986–2992 (2005)
374. M. Tesauro, F. Schinzari, V. Rovella, N. Di Daniele, D. Lauro, N. Mores et al., Ghrelin restores the endothelin 1/nitric oxide balance in patients with obesity-related metabolic syndrome. Hypertension 54(5), 995–1000 (2009)
375. N. Hedayati, S. Annambhotla, J. Jiang, X. Wang, H. Chai, P.H. Lin et al., Growth hormone-releasing peptide ghrelin inhibits homocysteine-induced endothelial dysfunction in porcine coronary arteries and human endothelial cells. J. Vasc. Surg. 49(1), 199–207 (2009)
376. D. Wang, H. Wang, P. Luo, A. Hwang, D. Sun, Y. Wang et al., Effects of ghrelin on homocysteine-induced dysfunction and inflammatory response in rat cardiac microvascular endothelial cells. Cell Biol. Int. 36(6), 511–517 (2012)
377. G. Togliatto, A. Trombetta, P. Dentelli, S. Gallo, A. Rosso, P. Cotogni et al., Unacylated ghrelin (UnAG) induces oxidative stress resistance in a glucose intolerance mouse model and peripheral artery disease by restoring endothelial cell miR-126 expression. Diabetes (2014). doi:10.2337/db14-0991
378. D. Zhang, W. Wang, Y. Zhou, Y. Chen, L. Han, Y. Liu et al., Ghrelin inhibits apoptosis induced by palmitate in rat aortic endothelial cells. Med. Sci. Monit. Basic Res. 16(12), 396–403 (2010)
379. Y. Xiang, Q. Li, M. Li, W. Wang, C. Cui, J. Zhang, Ghrelin inhibits AGEs-induced apoptosis in human endothelial cells involving ERK1/2 and PI3K/Akt pathways. Cell Biochem. Funct. 29(2), 149–155 (2011)
380. W.G. Li, D. Gavrila, X. Liu, L. Wang, S. Gunnlaugsson, L.L. Stoll et al., Ghrelin inhibits proinflammatory responses and nuclear factor-B activation in human endothelial cells. Circulation 109(18), 2221–2226 (2004)
381. B. Deng, F. Fang, T. Yang, Z. Yu, B. Zhang, X. Xie, Ghrelin inhibits AngII-induced expression of, IL-8, MCP-1 in human umbilical vein endothelial cells. Int. J. Clin. Exp. Med. 8(1), 579 (2015)
382. X. Liu, Q. Xiao, K. Zhao, Y. Gao, Ghrelin inhibits high glucose-induced PC12 cell apoptosis by regulating TLR4/NF-κB pathway. Inflammation 36(6), 1286–1294 (2013)
383. J. Zhu, C. Zheng, J. Chen, J. Luo, B. Su, Y. Huang et al., Ghrelin protects human umbilical vein endothelial cells against high glucose-induced apoptosis via mTOR/P70S6K signaling pathway. Peptides 52, 23–28 (2014)
384. X. Chen, Q. Chen, L. Wang, G. Li, Ghrelin induces cell migration through GHSR1a-mediated PI3K/Akt/eNOS/NO signaling pathway in endothelial progenitor cells. Metab., Clin. Exp. 62(5), 743–752 (2013)
385. G. Togliatto, A. Trombetta, P. Dentelli, A. Baragli, A. Rosso, R. Granata et al., Unacylated ghrelin rescues endothelial progenitor cell function in individuals with type 2 diabetes. Diabetes 59(4), 1016–1025 (2010)
386. L. Trovato, D. Gallo, F. Settanni, I. Gesmundo, E. Ghigo, R. Granata, Obestatin: is it really doing something. 42:175–85 (2014). doi:10.1159/000358346
387. R. Granata, D. Gallo, R.M. Luque, A. Baragli, F. Scarlatti, C. Grande et al., Obestatin regulates adipocyte function and protects against diet-induced insulin resistance and inflammation. FASEB J. 26(8), 3393–3411 (2012)
388. P. Gu, D. Kang, W. Wang, Y. Chen, Z. Zhao, H. Zheng et al., Relevance of plasma obestatin and early arteriosclerosis in patients with type 2 diabetes mellitus. J. Diabetes Res. (2013). doi:10.1155/2013/563919
389. A.J. Agnew, E. Robinson, C.M. McVicar, A.P. Harvey, I.H.A. Ali, J.E. Lindsay et al., The gastrointestinal peptide obestatin induces vascular relaxation via specific activation of endothelium-dependent NO signalling. Br. J. Pharmacol. 166(1), 327–338 (2012)